More information:
Access the news on Oslo Bors NewsWeb site

Annual Report 2022_SoftOx Solution AS

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS call GA 21 06 2023

More information:
Access the news on Oslo Bors NewsWeb site

More information:
Access the news on Oslo Bors NewsWeb site

For further information, please contact:

Geir Almås, Executive Chairman of SoftOx

Solutions AS Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599 or (+47) 977-59-071

OSLO – June 9, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, has entered into an agreement with the company’s creditors on a new pay back plan. In addition, the company has raised NOK 15 million in new equity and debt. New equity raised is NOK 3 million at NOK 8 per share. New debt is NOK 12 million maturing January 2024 with an interest of 25% for the period and warrants for buying shares for the total amount of NOK 42 million for NOK 8 per share. The creditors have agreed on a down payment plan where they get 25% before the end of June, 25% before the end of September and the final amount including overdue interest before the end of the year.

“We are currently exploring a number of exciting opportunities to commercialize our technology and I appreciate that our creditors have given us the leeway to continue these talks.

This, together with the capital raise, takes the company out of the stressed financial situation and gives the board time until the end of the year, to pursue these opportunities”, says CEO Geir Almaas at SoftOx. This, together with an agreement with the employees and the board members who has approved to delaying payments of salaries and debt for up to NOK 6 million on similar terms as the lenders in combination with a substantially cost reduction and funding from government funds has brought the company’s burn rate down to approximately NOK 1 million per month.

As stated in the stock exchange notice of 11th of May 2023, SoftOx has signed a Letter of Intent (LOI) with the Department of lmmunology and Microbiology (ISIM), Faculty of Health and Medical Sciences, University of Copenhagen, to outsource SoftOx’s product development saving huge costs for the company. The intention is to establish new and innovative solutions based on the SoftOx technology for fighting antimicrobial resistance and chronic infections in wounds and an inhaled broad spectrum of anti-infective treatment for the respiratory tract.

According to the company’s new strategy the company shall on its own only take technologies up to proof of concept. Afterwards SoftOx shall explore the opportunities of taking on a strategic partner for further development, selling parts or the whole technology platform or in combination with regional rights. At the moment wound care and disinfection both got early proof of concept.

“Our unique technology with very encouraging clinical results in early phase answers some of the biggest health challenges the world is facing, strategic talk with potential commercial partners, agreement with the University of Copenhagen and solid reduction in overheads and future product development, reduce the company’s need for future funding and makes the board confident that it has managed to put the company in a very good position for future development”, says Almaas.

More information:
Access the news on Oslo Bors NewsWeb site

For further information, please contact:

Geir Almås, Executive Chairman of SoftOx

Solutions AS Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599 or (+47) 977-59-071

MINUTES FROM AN EXTRAORDINARY GENERAL MEETING SOFTOX SOLUTIONS AS

More information:
Access the news on Oslo Bors NewsWeb site

Reference is made to the stock exchange announcements by the Company on 11 May,
27 March and 13 March 2023 regarding the Company’s efforts to secure and
strengthen the Company’s liquidity in the short and long term, and the Company’s
work to explore solutions to financially strengthen the Company.

On 11 May 2023, the Company announced that it had secured interim financing
through a NOK 9 million funding from certain shareholders and investors. In the
first round of funding, which may be increased to an aggregate amount of NOK 16
million, the funds will be 20% as equity and 80% as a loan to the Company’s
subsidiary Water Innovation AB (WIAB) (the “WIAB Loan”). The equity will be
contributed in a private placement of minimum NOK 1.8 million and maximum NOK
3.2 million new shares at a subscription price per share of NOK 8 per new share
(the “Private Placement”). The WIAB Loan, which will be in the aggregate of
minimum NOK 7.2 million and maximum 12.8 million, will mature on 31 January
2024, at which point the interest accrued on the loan shall be 25%. The WIAB
Loan may be converted to new shares in the Company at a subscription price of
NOK 8 per share at maturity of the loan (i.e. in January 2024), or at an earlier
capital raise in the Company, at the lenders discretion, provided, however, that
in the event of an advance conversion of the WIAB Loan, the interests accrued on
the individual lenders loan amount shall be reduced proportionally to reflect
the shorter period of interests accrued.

Further, the board of directors proposes that the Company issues minimum
2,700,000 and maximum 4,800,000 warrants (the “Warrants”), to be finally
determined when the final amount of funding in the first round has been fixed,
and no later than on the day before for general meeting. The number of Warrants
shall be calculated as follows: The aggregate amount of the WIAB Loan multiplied
by 3 and then divided by 8 (which is the offer price in the Private Placement.
The Warrants are to be allocated amongst the lenders, proportionally to the
respective amount of the WIAB Loan. Each Warrant will give the holder the right
to subscribe for and be allocated one new share in the Company at a subscription
price of NOK 8 per new share. 1/3 of the Warrants will expire on 31 January
2024, when Warrants can be exercised against conversion of debt, while the
remaining 2/3 of the Warrants will expire on the date falling five years after
issuance, i.e. on 29th of May 2028. The Warrants will not be transferrable.
Current shareholders who wish to participate in the WIAB Loan and the Private
Placement with a total investment amount of minimum NOK 250,000 can contact the
chairman of the Company. There can be no guarantee that shareholders are able or
allowed to participate.

The net proceeds from the WIAB Loan will be used by WIAB to secure the Company’s
intellectual property and pay back a loan to the parent company (SoftOx
Solutions AS). The net proceeds from the Private Placement will be used for
general corporate purposes, including payment of some of the debt in the
Company. At current cost and activity levels of the Company, and assuming the
minimum capital raised (NOK 9 million) will give the Company a runway of
approximately 6 months, any further capital raised in this first round will
solely be used to partly pay down the Company’s short-term debt, which is
currently approx. NOK 20 million.

As part of program for financial restructuring of the Company, the Company has
reduced the cost of running the Company from approx. NOK 8 million per month to
approx. NOK 1 million per month. As part of that program, the management and
members of the board have accepted to partly postpone payment of accrued and
future salaries, board remuneration and consulting fees till end of 1st quarter
2024 with an aggregate amount of maximum NOK 6 million. The board of directors
thus proposes to issue 2,250,000 warrants to be granted these employees and
board members, free of charge and otherwise on the same terms and conditions as
the Warrants. Provided, however that, 1/3 of the warrants granted must be
exercised before 31 March 2024 and will be conditional on the employment or
directorship not having been terminated at the time, while the remaining 2/3 of
the warrants may be exercised within 29th of May 2028 with no such condition.
Further, as also announced in the 11 May 2023 stock exchange announcement, the
Board of Directors intends to raise NOK 20 to 50 million in new equity by way of
a rights issue or other structures, to be determined by the board of directors
based on prevailing market conditions and terms deemed to be overall in the best
interest of the Company. The board of directors has thus proposed that it is
granted an authorisation to issue new shares.

The proposed resolutions regarding the Private Placement, issuances of warrants
and authorisation to the board of directors to issue shares are required in
order to secure the Company’s funding need going forward. It will thus be
proposed that items 5 – 7 are voted over jointly at the general meeting.
The Private Placement entails a deviation of existing shareholders’ preferential
rights to subscribe new shares in the Company. As further described in the stock
exchange announcement from the Company on 23 May 2023, the board has considered
the requirements for equal treatment of shareholders set out in the rules for
issuers admitted to trading on Euronext Growth Oslo, and has concluded that the
Private Placement is compliant with the equal treatment requirements to which
the Company is subject. This is inter alia based on the Company’s severely
constrained liquidity situation, the Offer Price is at a premium compared to the
trading price of the share on the date preceding this notice, that the Company
has explored several financing solutions and concluded that the current proposal
is considered necessary in order to secure the short-term liquidity needs of the
Company. Further, a repair issue is deemed to require too much resources and
costs for the Company at this time, and the board of directors instead intends
to carry out a rights issue or similar capital raise involving a broader
shareholder base.

With respect to events following the last balance sheet date that are material
for the Company, reference is made to interim reports, stock exchange
announcements and information published by the Company through the Oslo Stock
Exchange’s information system.

For further information, please contact:

Geir Almås, Executive Chairman of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599 or (+47) 977-59-071

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – May 11, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway,has secured financing of approx. NOK 9 million which gives the Company a runway of approx. 6 months within which the Company plans to raise further capital through a contemplated pre-emptive rights issue towards existing shareholders.

“This raise of funds, a material change of strategy including a considerable reduction of burn rate, expected further grants and prepaid assets ready for sale, is expected to fully finance the company’s future product development both for the military and the civil markets.” says Executive Chairman of SoftOx Solutions AS, Geir Almås.

As stated in previous stock exchange notice, including the announcement made March 27 and March 23, the Company has over some time been exploring funding alternatives to secure the Company’s operations and liabilities, and that it would restructure and explore strategic alternatives. This work has now been further progressed, through the contemplated financing and the restructuring of the company. The restructuring involves securing key personnel and signing a Letter of Intent (LOI) with the Department of lmmunology and Microbiology (ISIM), Faculty of Health and Medical Sciences, University of Copenhagen, who will now lead the future product development as further described below.

Outsourcing the Company’s product development

The two parties state in the LoI that the potential partnership is based on the highly promising clinical results observed in treatment of chronic wounds, the proof of concept for treatment of influenza in mice and prevention of Sendai virus (parainfluenza) in mice, safety and tolerability studies of SoftOx lnhalation Solution (SIS) and the two parties’ partnership in the European Defense Fund’s COUNTERACT consortium. The agreement is conditional upon fully financing of SoftOx Solutions including payment of debts and sufficient runway.

“At the University of Copenhagen we find some of the best researchers in the world within the field of antimicrobial resistance and chronic infections. This partnership is a big step towards our goal of developing the future solutions for treatment of virucidal infections in the respiratory tract and infections in chronic wounds”, says Almås.

Together the two parties intend to establish new and innovative solutions based on the SoftOx technology for fighting antimicrobial resistance and chronic infections in wounds and together an inhaled broad spectrum of anti-infective treatment for the respiratory tract.

The two parties state in the LOI: “The first development project the parties want to move from SoftOx to the University of Copenhagen is the research and development of medical countermeasure solutions against biological threats and for civil preparedness toward the next pandemic. The cost of University of Copenhagen’s work packages will be covered by future payments of grants already awarded by European Defense Fund and The Norwegian Ministry of Defense.”

“SoftOx furthermore intends to outsource its civil product development of the SoftOx lnhalation Solution for treatment of influenza-like illnesses and prevention of hospital-acquired pneumonia (HAP) to the University of Copenhagen to ensure that proof of concept in humans”, says Thomas Bjarnsholt, Chief Scientific Officer at SoftOx Solutions, and professor within bacteriology at the University of Copenhagen. Future projects at University of Copenhagen depends on funding from SoftOx Solutions AS and will give the investors of SoftOx a great opportunity of conducting an effect study in humans on its inhalation solution for a much lower price than originally planned.

SoftOx will keep the commercial rights and ownership to the technology.

Reducing the burn rate, securing key personnel

The Company has reduced the burn rate in the holding company SoftOx Solutions AS from approx. NOK 8 million per month to approx. NOK 1 million per month. This reduction has been achieved through layoffs, closing down our own production facilities for GMP production and other outsourcing of activities.

The Company will in the future only retain a small staff to coordinate and lead the company’s product development.

As already mentioned the University of Copenhagen will take over and perform SoftOx’ scientific development under the European Defense Funds Medical Counter Measurement program. SoftOx Defense Solutions AS will have a core scientific team paid by funding from already received grants working on the program. “By doing this our burn rate has decreased significantly and at the same time securing a strategic collaboration with the University of Copenhagen and University hospitals, we get the ability to do future product development with top notch scientific and clinical teams”, says Almås.

Divestment or co-fund technology after early proof of concept

Based on a change in strategy, where the Company will develop its products to the stage of proof of concept in humans, SoftOx Solutions has started a process to either divest the wound care and the disinfection technology or carve it out in in separate funded companies with a clear pathway of a well-timed potential divestment of ownership.

“We have several leads both within wound care and disinfection, which we will explore further. The interest is solid, and we are optimistic”, says Almås.

Further details regarding first and second round of funding

NOK 9 million is already committed by way of share capital contribution and loan and the Company is in close dialog with other investors with the aim to increase the first round of funding to NOK 16 million in total. 80% of the funding will be in the form of a loan to the group subsidiary Water Innovation AB (WIAB), which will in turn use the funds to secure the company’s intellectual property and pay back a loan to the holding company. The remaining 20% of the funding will be by way of a private placement in SoftOx Solutions AS with up to 400.000 new shares to be subscribed at a subscription price of NOK 8 per share. The loan, which matures on the 31st of January 2024 and will be repaid with an amount equal to 125% of the loan. The lender will at the time of repayment of the loan have a warrant to buy share an amount equal to the original loan with strike NOK 8 per share. Each lender will also receive a number of warrants amounting to double the gross proceeds paid by the respective investor in the first funding round (i.e. share capital and loan amount). These warrants will expire on the date falling 5 years after the issue. In addition to the NOK 9-16 million in the form of equity and loans in the first funding round, the Board of Directors also expects to propose to the general meeting that it receives an authorization to increase the share capital of the Company by way of conversion of up to NOK 5 million in debt to employees and their companies on to shares with a share price of NOK 8 per share. Each lender will also receive a number of warrants amounting to double the gross proceeds paid by the respective investor in the first funding round (i.e. share capital and loan amount). These warrants will expire on the date falling 5 years after the issue.

Gross proceeds of NOK 20 to 50 million

In order to secure a well-planned process for the divestment of technology and to pay off its accumulated debt, the Company intends to raise NOK 20 to 50 million in a second round of funding. This is expected to be in the form of a rights issue, but other structures may be considered, depending on market conditions and investor appetite. Under the condition that the Company in the second round raise NOK 50 million at NOK 8 per share, today’s shareholders will keep ownership of 63,1% of the total amount of shares in the company after the conversion of today’s convertible loan and the execution of the warrants.

The process planning for securing this financing has started and the Company expects to conclude this second round of financing at the latest by the end of the third quarter 2023.

The extraordinary General meeting to approve the share issue, the subscription rights and the authorisations to the Board of Directors to issue new shares will be convened in due course.

For further information, please contact:

Geir Almås, Executive Chairman of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599 or (+47) 977-59-071

More information:
Access the news on Oslo Bors NewsWeb site

Financial calendar for SoftOx Solutions AS

FINANCIAL YEAR 2022

14.06.2023 – Annual Report

21.06.2023 – Annual General Meeting

FINANCIAL YEAR 2023

26.09.2023 – Half-yearly Report

20.03.2024 – Annual Report

28.03.2024 – Annual General Meeting

14.06.2023 – Quarterly Report – Q1

26.10.2023 – Quarterly Report – Q3

15.02.2024 – Quarterly Report – Q4

This information is published pursuant to the requirements set out in the Continuing obligations.

More information:
Access the news on Oslo Bors NewsWeb site

Financial calendar for SoftOx Solutions AS

FINANCIAL YEAR 2022

14.06.2023 – Annual Report

21.06.2023 – Annual General Meeting

FINANCIAL YEAR 2023

26.09.2023 – Half-yearly Report

20.03.2024 – Annual Report

28.03.2024 – Annual General Meeting

03.05.2023 – Quarterly Report – Q1

26.10.2023 – Quarterly Report – Q3

15.02.2024 – Quarterly Report – Q4

This information is published pursuant to the requirements set out in the Continuing obligations.

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – March 27, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”) today announces that its Board of Directors has decided to temporarily lay off employees to save costs during a period of financing and restructuring of the Company. As a result of this decision, SoftOx Solutions Denmark has been closed down and key personnel will be reengaged.

During the temporary layoff period, the Company will continue the work on securing financing for further development of SoftOx Solutions AS.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – March 24, 2023: Board member Kari Myren has informed the board of SoftOx Solutions AS that she will resign from the board with immediate effect. The Company are grateful for her service and her contribution to development of the company and its technology.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

The company has explored several options, including interest for a private placement, but is still in need of new capital to fund the company’s operations and liabilities. It will continue its efforts to solve the short- and long-term liquidity needs, which may involve a wider capital raising, divestment of assets or strategy changes. The company will update the market once it has specific news.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – March 20, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, hosted a webcast presentation today at 13:00 (CET). Due to technical difficulties and network issues, the presentation was unable to be streamed during the webcast and the webcast was therefore cut short.

The introduction, presentation and Q&A session are now posted on SoftOx’s website and can be found at https://soft-ox.com/investor-presentations/

Additional questions can be sent to ir@soft-ox.com.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – March 17, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, will host a webcast presentation on Monday, March 20, 2023, at 13:00 (CET).

Please register for the presentation at https://soft-ox.com/investor-presentations/

The presentation will be held in English and followed by a Q&A session. Questions can be submitted in advance to ir@soft-ox.com.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

The Norwegian Environment Agency has today approved SoftOx’s biocidal product family for hand and surface disinfection for use in the Norwegian market. The approval is a mutual recognition in sequence based on the approval by the Swedish Chemicals Agency (KemI) on 19 October 2022. With this approval, the company is now approved for up to 10 years in line with Biocidal Products Regulation.

Decision

“The Norwegian Environment Agency grants SoftOx Solutions AS an authorisation for the biocidal product family SoftOx Disinfectants on the Norwegian market. The authorisation is granted from 9 March 2023 to 17 October 2032 with the authorisation number NO-2023-0240.”

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

With reference to the stock exchange announcements from SoftOx Solutions AS (“SoftOx” or the “Company”) on February 15, 2023, on the challenging liquidity situation and on March 8, 2023, the webcast presentation. The Company provides an update on the financing process and the company status.

Financing

SoftOx is working diligently on securing both its short-term and long-term financing. The company is in close dialogue with both existing stakeholders and interested outside investors. SoftOx is currently in discussions with a select number of investors, and the company is evaluating different potential models. The aim is to secure approx. NOK 40 million, to secure the company runway for 6 months. Payment from the European Defence Fund is expected but not included in the Company’s budgets going forward.

If the Company decides to propose a solution with a basis from new investors, it is the intention that the existing shareholders will be given ample opportunities to also participate. SoftOx would like to underline that there is uncertainty as to whether a solution with outside investors may materialise at this point.

Company status

SoftOx has recently reached several important milestones in its product development and believes that the underlying values are material. All completed studies have shown excellent clinical results and confirmed safety and tolerability with a broad spectrum of antiviral and antimicrobial effects. In the treatment for leg ulcers, it was observed over 99% reduction in bacterial burden in the wound together with observed dose dependent reduction in wound size with 24% reduction in wound size in the group which received treatment one time per day in 5 days and 36% reduction in wound size in the group which received treatment with SoftOx two times per day in 5 days. External health economic models from EXCITE International estimate the health economic saving by faster wound healing and avoiding infections in leg ulcers to be up to USD 6,404 per patient, which would give up to USD 14 billion in reduced health care cost in the US alone. For the infectious disease (SIS) project, the Company observed infection prevention ability in an influenza-like mouse model together with tolerability and safety in phase 1.

As material financing discussions are ongoing, the company has decided to postpone its announced extended presentation scheduled for March 14, 2023. However, attached to this release is an extended presentation that describes the technology development, results and progress in detail.

SoftOx will revert with further updates in due course.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

With reference to the stock exchange announcement from SoftOx Solutions AS (“SoftOx” or the “Company”) on March 3, 2023, the webcast presentation, due to take place on March 8, 2023, has been postponed. The Board of Directors and the management are considering different financing solutions and this process will be further addressed during the presentation.

The webcast presentation by management will take place on Tuesday, March 14th at 10:00. Please register for the presentation by contacting ir@soft-ox.com.

The presentation will be held in English and followed by a Q&A session. Questions can be submitted in advance to ir@soft-ox.com.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – March 3, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, will host a webcast presentation on Wednesday, March 8, 2023 at 11:00 (CET). The presentation and related materials will be made available at https://soft-ox.com/investor-presentations/ on the same day.

Please register for the presentation before March 8th, at 08:00 (CET) by sending your registration to ir@soft-ox.com.

The presentation will be held in English and followed by a Q&A session. Questions can be submitted in advance to ir@soft-ox.com.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – February 15, 2023: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, today announces its results for the fourth quarter.

“2022 was a defining year for the SoftOx technology. We delivered promising results from two clinical trials and gained the approval for our disinfectants in Sweden. The conditions and funding in connection with the European Defence Fund have also been agreed upon, aiding a clear strategy and set of priorities for business development,” said Christian Harstad, Interim Chief Executive Officer of SoftOx Solutions.

Q4 highlights

(Figures in brackets represent the corresponding period in 2021 unless stated otherwise)

• The final study report of the SBE-01 Phase 1 study confirmed safety and tolerability in patients with chronic leg wounds and provided indications of clinical efficacy with dose-dependent reductions in bacterial burden and wound size
• Final approval received on biocidal products application for hand and surface disinfection from the Swedish Chemicals Agency (KemI). This approval allows SoftOx to sell its disinfection products in Sweden outside the healthcare segment
• Convertible loan secured from existing shareholders of NOK 25 million and SoftOx refinanced the NOK 15 million convertible loan as reported on 28 June 2022
• Following the extraordinary general meeting on 9 December 2022, the Board of Directors strengthened with the additions of Henrik Nielsen, Adrian Bignami and Jørgen Berggrav, together with the existing members Kari Myren and Olav Jarlsby. Geir Almås was elected Executive Chairman of the Board and has stepped down from his role as Chief Executive Officer of SoftOx
• Effective 1 January 2023, Christian Harstad was appointed interim CEO bringing his skill set, experience and diverse network in the defence sector to SoftOx as the company progresses in its collaborations with the European Defence Fund and the US Naval Medical Research Center
• Harald Sætvedt joined as Chief Financial Officer in January 2023 bringing his solid experience in international corporate finance
• Q4 pre-tax results ended with a loss of NOK 25.5 million (loss of NOK 20.5 million). Results are characterized by continuing primary research and development activities

Subsequent events/near-term considerations

• In early January 2023, SoftOx announced the signing of the final grant agreement with the COUNTERACT Consortium and the European Defence Fund (EDF). The project involves key European players to develop a military medical countermeasure inhalator based on the SoftOx technology
• The EDF project involved a partial prepayment of approximately EUR 2.25 million upon signature of the agreement. However, the project coordinator has communicated a change in the prepayment plan, such that SoftOx will receive the prepayment in arrears. The first prepayment will be approximately EUR 843,000 which is to be paid in the first quarter 2023. The remaining prepayment is expected to be paid in arrears in the fourth quarter of 2023 and 2024
• The revised timing of the prepayment has created liquidity issues for the company. SoftOx is working intensively to secure short-term financing of up to NOK 25 million to fund operations over the next few months. Furthermore, the company has initiated a process to address and secure a longer-term funding of the company. The company believes that the solid clinical results in both the wound care and respiratory projects, combined with a well-defined development path to market, create a good foundation for attracting high quality and competent investors

The Company will not host a presentation and Q&A session on this occasion. An extended presentation will be held during week 9. Further information on the presentation and registration details will follow.

For further information, please contact:
Christian Harstad, Interim CEO of SoftOx Solutions AS, or
Geir Almås, Executive Chairman of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS Q4 2022 Report

Reference is made to the stock exchange announcement from SoftOx Solutions AS on 20 July 2022 regarding the result of the European Defence Fund (EDF) application and The Commissariat a l’Energie Atomique et aux Energies Alternatives press release on the 6th of January 2023.

SoftOx Solutions , a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, announces the signing of the final grant agreement for the COUNTERACT Consortium – which includes SoftOx – with the European Defence Fund. COUNTERACT aims to reinforce the European Union’s preparedness for chemical, biological, radiological and nuclear (CBRN)-type threats. The project includes pre-clinical and clinical studies on the safety and efficiency of medical countermeasures targeting CBRN-type threats.

The project will cover a four-year period and started in December 2022. This project brings together key European players: from 11 EU Member states (five universities; three technological research bodies; ten public research institutes; eight SME and start-ups). 19 of these are related to the part of the project where SoftOx is involved. SoftOx is a part of the COUNTERACT consortium, and the SoftOx technology is one of the three main technologies forming the basis for the grant. This funding of NOK 97 million related to the first of four possible phases, will contribute to the development of an MCM inhalator based on the SoftOx technology. EDF communicates a willingness to continue giving support to technologies that deliver results in line with expectations. New calls will be announced on an annual basis through 2027.

“This first grant is a significant recognition of our work, and we are proud that the EU Commission has invested in the SoftOx technology to strengthen preparedness against chemical and biological weapons,” said Christian Harstad, interim CEO of SoftOx. “This project with the COUNTERACT Consortium gives us the opportunity to further develop our inhalation solution for which there is a significant need in both the civil and military markets. This grant states our potential to double the size of the markets we aim to approach with the SoftOx inhalation solution.”

Due to expected synergies, it is anticipated that participating in the EDF program will reduce the need for investments both on the civil and defence development of a SoftOx inhalation solution. The civilian market opportunity is larger because of the inhalator’s potential as a first-line treatment of human respiratory infections.

It is the SoftOx subsidiary SoftOx Defense Solutions AS that is part of the COUNTERACT consortium.

COUNTERACT objectives:

• Develop and mature four types of medical countermeasures, for which two will aim to achieve the stage of application for authorization to place the products on the market by the European Medicines Agency;
• Promote EU independence in the development and production of countermeasures against NRBC threats by establishing a European network of sustainable industries,research laboratories, research bodies and clinical centers, aiming to achieve a flexible and efficient umbrella structure for the health sector targeting defense;
• Draw up a road map for the development of the future generation of medical countermeasures against current and future threats, simplify the process for obtaining market authorizations, guarantee independent EU supply chains and prepare storage and deployment strategies.

For any enquiries, please contact:
Geir Almås, Chair of the board of SoftOx Solutions AS (+47) 977 59 071
Christian Harstad, Interim CEO of SoftOx Solutions AS (+47) 926 58 766
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

CP Counteract VF English.pdf

• This first-in-human clinical study demonstrated that SoftOx Biofilm Eradicator (SBE) applied on chronic leg wounds was safe and well-tolerated
• There were no statistically significant differences in the evaluation of pain during and after the wound cleaning procedure comparing SBE with placebo (Saline).
• Treatment with all SBE formulations consistently reduced the absolute number of bacteria in the wound compared with pre-treatment
• A dose-dependent reduction in wound size was observed in the multiple-dosing SBE treatment groups

OSLO – December 15, 2022 – SoftOx Solutions AS (“SoftOx” or the “Company”), a clinical-stage pharmaceutical and MedTech company based in Norway, announces
that the Company has received the final report and analysis of its Phase 1 study evaluating the safety and tolerability of SoftOx Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx’s antimicrobial solution for the treatment of chronic wounds.

SBE-01 is a first-in-human study investigating the safety, tolerability, and antimicrobial efficacy of single and multiple doses of SBE in patients with chronic leg wounds. The Phase 1 study was divided into two parts: a randomized, blinded, Single Ascending Dose (SAD) phase, followed by an open label, Multiple Ascending Dose (MAD) phase, where patients were treated once-daily or twice-daily over five days.

Key findings
The final report reaffirms previous findings that SBE is safe and well-tolerated by patients suffering from chronic leg wounds. There were no statistically significant differences in the evaluation of pain during and after the wound cleaning procedure comparing SBE with placebo. The study found that formulations of SBE consistently reduced the bacterial burden in the wound compared with pre-treatment. There was also evidence of wound healing with a reduction in wound area of between 24 to 36% after just 5 days’ treatment.

Thomas Bjarnsholt, Chief Scientific Officer at SoftOx, said: “According to the World Health Organization, antimicrobial resistance is one of the largest threats to human health, which is why it is critical to develop new and innovative ways to tackle bacterial infections. These results clearly suggest that the SBE solution is safe and well-tolerated by patients and can significantly reduce the overall bacterial burden in wounds, ultimately promoting wound healing. Taken together with previous clinical studies, these data are early proof-of-concept for the technology as a potential treatment candidate for patients suffering from chronic wounds worldwide.”

Next steps
Having demonstrated early proof-of-concept for the SBE project and in accordance with the Company’s corporate strategy, SoftOx will seek a strategic partner to further develop and advance its wound care segment within acute and chronic indications.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Christopher Burton, CMO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
biopharmaceutical and MedTech company based in Oslo, with the goal of reducing
the spread of infection and emergence of antimicrobial resistance. For more
information on SoftOx, visit www.soft-ox.com

About biofilm and antimicrobial resistance
Biofilm in chronic wounds is a cluster of bacteria within a matrix, which makes it difficult for today’s antibiotics to effectively eradicate the infection in chronic wounds. Up to 2 per cent of the population of developed countries are projected to experience a chronic wound during their lifetime. Within organized biofilms, bacteria are more resistant to antibiotics and immune responses, making clinical treatment of biofilm infection difficult.

Antimicrobial resistance – significant unmet need
Combination antibiotic therapy and physical removal of biofilms are commonly used forms of treatment for biofilm-associated infections. Still, there remains a significant unmet need for new and innovative approaches to tackling biofilm and multidrug-resistant bacteria. Previous studies have shown that antimicrobial-resistant bacteria are present in more than 50 per cent of chronic wounds. According to the World Health Organization (WHO), antimicrobial resistance is one of the largest threats to human health. In 2019 alone, antimicrobial-resistant bacteria contributed to 4.95 million deaths worldwide.

More information:
Access the news on Oslo Bors NewsWeb site

An extraordinary general meeting of SoftOx Solutions AS (the “Company”) was held today on 9 December 2022 at 12.00. The general meeting was held both as a
physical and electronic meeting. 2 806 781 shares were represented, corresponding to 27,14 % of the Company’s total number of shares.

The general meeting approved all the proposals on the agenda in line with the notice dated 2 December 2022. The board of directors has now been strengthened
with the additions of Henrik Nielsen, Adrian Bignami and Jørgen Berggrav, together with the existing members Kari Myren and Olav Jarlsby. CEO, Geir Almås, steps up to become full-time Executive Chairman of the Board. He will therefore resign as CEO as soon as the new board has appointed an interim CEO.

Signed minutes from the general meeting are attached to this announcement and will be made available on the Company’s website.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing the spread of infection and emergence of antimicrobial resistance.

For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

 577836_SoftOx Solutions AS_EGM referat_09122022 – signert.pdf
  577836_Appendix 1_Voting results.pdf
  577836_SoftOx Solutions_EGM Minutes_09122022_eng – signert.pdf
  577836_Appendix 2_Shareholder proposal.pdf

• Current CEO Geir Almås proposed as new chairman of SoftOx Solutions AS
• Three additional board members proposed – Henrik Nielsen, Adrian Bignami and Jørgen Berggrav

Oslo, Norway – 2 December 2022: The board of directors of SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, hereby convenes, upon the request of certain large shareholders (including the CEO, Geir Almås), an extraordinary general meeting to be held on 9 December 2022 for the election of a new chairman and new board members.

The notice to the EGM and the proposal from the shareholders are attached. A summary of the shareholders proposal is included in the following:

“After several major achievements in the past half year including the European Defence Fund grant and successful completion of Phase 1 of the SoftOx Biofilm Eradicator, the Company’s largest shareholders, representing 26 per cent of the total number of outstanding shares, have proposed changes to the current Board of Directors and management team. The shareholder group, including Dinge Invest AS, Hermod Farms AS, Kristian Almås, Almhaug Bolig AS, all companies associated with Kristian and Geir Almås, proposes that CEO Geir Hermod Almås step down from his current role as CEO and transition to chairman of SoftOx.

To further strengthen both the board of directors and management team, the shareholder group proposes the addition of Henrik Nielsen, Adrian Bignami and Jørgen Berggrav as elected members of the board. Together with the existing members Kari Myren and Olav Jarlsby, the new members will represent an international board with interests and expertise reflective of the company’s current and future business pursuits.

Henrik J. Nielsen is the founder and CEO of CAP Partner, a conference handling and consulting firm based in Frederiksberg, Denmark, and Director of the European Wound Management Association, which is one of the largest not-for-profit umbrella organisations in the world within the field of scientific and clinical wound care. Nielsen is an expert in association management, advocacy, fundraising and organization and has provided many years of expertise in the medical device area as a consultant.

Adrian Bignami is one of the early co-inventors of the SoftOx technology and is currently the Vice President of Finance, Business Planning and Analysis at C4 Therapeutics, Inc., a clinical-stage biotechnology company in the US. He has over 20 years of experience in management consulting, investment banking, entrepreneurship, business development and corporate finance across the pharmaceutical and biotechnology sectors.

Jørgen Berggrav (Rear Admiral Rtd) has served as the Senior Advisor of SoftOx Defense Solutions since September 2022. Berggrav has held many diverse roles in the Armed Forces including as Director General in the Ministry of Defence, representative of Europe to the Supreme Allied Commander Transformation and representative of the Chief of Defence at NATO’s operational command, SHAPE.

SoftOx Solutions AS hereby calls for an Extraordinary General Meeting (EGM) to be held at Martin Linges vei 25, 1364 Fornebu on 9 December 2022 at 12:00 hours (CET). Shareholders are encouraged to submit proxies with or without voting instructions in advance of the general meeting.”

Shareholders wishing to attend the Extraordinary General Meeting, in person or by proxy, must complete and return the attendance form or proxy form to the SoftOx IR email ir@soft-ox.com no later than 8 December 2022 at 12:00.

The notice of the EGM is attached. All documents regarding the EGM are also available on the Company’s website:
https://soft-ox.com/stock-market-announcements/

The following items are on the agenda: (i) Election of new Chair of the Board of Directors and changes to the board (ii) Remuneration to the chair of the board and board members.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing the spread of infection and emergence of antimicrobial resistance.

For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

  577287_SoftOx Solutions AS_ENG_02.12.2022_Notice.pdf
  577287_Proposal_Shareholder group 02-12-2022.pdf

Oslo, Norway, November 3, 2022: Geir H. Almås, CEO of SoftOx Solutions AS, a person discharging managerial responsibilities in SoftOx Solutions AS (the
“Company”), has notified the Company of a transfer of a part of the convertible loan issued by the Company, as announced on October 11 2022.

Please refer to the attached form for further details about the transfer.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftfOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information pursuant to MAR article 7, and is publicly disclosed in accordance with MAR article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
biopharmaceutical and MedTech company based in Oslo, with the goal of reducing
the spread of infection and emergence of antimicrobial resistance. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

  574708_Melding om transaksjoner utført av personer med ledelsesansvar (primærinnsidere) og deres nærsta°ende (KRT-1500).pdf

OSLO – October 26, 2022: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, today announces its results for the third quarter of 2022.

“In the third quarter of 2022, SoftOx achieved two major milestones: the selection of our technology by the European Defence Fund (EDF) to develop countermeasures against CBRN threats and the end of the Phase 1 study evaluating the safety and tolerability of the SoftOx Biofilm Eradicator. Both accomplishments were years in the making and represent the persistence, expertise and commitment of the SoftOx team.”

“The company is in an opportune position to initiate and continue talks with European and international market players. We are now focused on ending the year with successful clinical results and continue exploring opportunities to develop our exciting platform technology,” said Geir Almås, Chief Executive Officer of SoftOx Solutions.

Operational highlights
• SoftOx announced the early completion of the Phase 1 SBE-01 trial, with positive results of the SoftOx Biofilm Eradicator (SBE) in treating chronic wounds. SBE was demonstrated to be safe and well tolerated as well as reducing the bacterial burden and improving wound healing in chronic leg wounds.

• SoftOx received final approval on biocidal products application for hand and surface disinfection from the Swedish Chemicals Agency (KemI). This approval allows SoftOx to sell its disinfection products in Sweden.

• The SoftOx technology, through its subsidiary SoftOx Defense Solutions (SDS), was granted NOK 97 million from the European Defence Fund to develop a military inhalation solution for the EU and its allies as part of a pan-European consortium.

• SDS’s leadership team was strengthened with the addition of Jørgen Berggrav as Senior Advisor and Johan Christian Harstad as Project Director.

Financial highlights
(Figures in brackets represent the corresponding period in 2021 unless stated otherwise)

• Q3 pre-tax results ended with a loss of NOK 23,7 million (loss of 22 million). Results are characterized by high levels of activity in research and development.

• Total operating expenses for the third quarter were NOK 25.3 million (NOK 23,4 million)

• Cash and cash equivalents amounted to NOK 3.2 million at the end of the second quarter (NOK 16.6 million)

• In October, SoftOx secured a convertible loan from existing shareholders for NOK 25 million and refinanced the NOK 15 million convertible loan as reported on 28 June 2022.

Presentation details
The results will be presented by the management via webcast at 09:00 (CET).

To register for the presentation, click the following link:
https://teams.microsoft.com/registration/GPWsOGT7vUCuf-It04UbWQ,oEPfirp3r0GbFmWNBzTZNg,ebnx2uZTkE2EPvewJm782g,A7wyP47zO0yXrzMTR20aXA,QniapSBGZ0urCimjTSRqIw,ziH9X8hk9U2QqA8bEDZFxg?mode=read&tenantId=38acf518-fb64-40bd-ae7f-e22dd3851b59

The presentation will be held in English and followed by a Q&A session.

For any questions or interview requests, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com Phone:
Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing the spread of infection and emergence of antimicrobial resistance. For
more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

→  573901_SoftOx Solutions AS_Q3 presentation 2022.pdf
→  573901_SoftOx Solutions AS_Q3 report 2022.pdf

OSLO – October 24, 2022: SoftOx Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, will
release its third quarter 2022 results on Wednesday, October 26, 2022 at 07:00 (CET). The report and related materials will be made available at
https://soft-ox.com/financial-calendar-reports/.

At 9:00 (CET) on the same day, the management will host a webcast presentation in English. Please register for the presentation using the link below.

Registration:

https://teams.microsoft.com/registration/GPWsOGT7vUCuf-It04UbWQ,oEPfirp3r0GbFmWNBzTZNg,ebnx2uZTkE2EPvewJm782g,A7wyP47zO0yXrzMTR20aXA,QniapSBGZ0urCimjTSRqIw,ziH9X8hk9U2QqA8bEDZFxg?mode=read&tenantId=38acf518-fb64-40bd-ae7f-e22dd3851b59

The presentation will be followed by a Q&A session. Questions can be submitted in advance to ir@soft-ox.com.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – October 19, 2022: Softox Solutions AS (“SoftOx” or the “Company”), a medtech and clinical-stage pharmaceutical company with a separate disinfection branch in Norway, today received the final approval on its application for the SoftOx biocidal product family for hand- and surface disinfection from the Swedish Chemicals Agency (KemI). This approval allows SoftOx to sell its disinfection products in Sweden.

“This is a great day for SoftOx,” said Geir Almås, CEO of SoftOx Solutions. “When we decide to enter other European markets, this approval will strongly
increase the probability of our disinfection products being approved by the EU. Following our business development strategy, we will now carefully evaluate the opportunities to partner up with suitable companies that can bring our disinfection technology to market,” Almås continued.

SoftOx can use this approval as a basis for new applications — mutual recognition in sequence — in any European market. As the Swedish authorities have diligently evaluated and approved the application, the mutual recognition process, described in the Biocidal Products Regulation (BPR), is considered a less complex and less expensive process.

“This approval documents that our technology is valid and that the products are effective and safe. I am proud of the team, which has successfully seen this project through to where we are today,” said Hans Jørgen Holum, SoftOx’s Project Manager of Biocides.

A safe and effective alternative to alcohol-based disinfectants
In addition, this approval may provide opportunities in markets outside Europe that normally rely on either EU or US regulatory decisions.

“This approval comes in addition to several other documented advantages of our solution. We have reference customers in Norwegian and Swedish hospitals and clinical documentation of skin friendliness. The Norwegian Defence Research Establishment (FFI) also published a positive data analysis, which showed that the SoftOx disinfectant reduced the level of volatile organic compounds in the air during an intervention period by 30-60% when compared with alcohol-based disinfectants, improving employees’ health, safety and environment. With this approval in place, we are confident moving forward with our unique and effective disinfectant technology for both civil and military applications,” said Almås.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with
the goal of reducing the spread of infection and emergence of antimicrobial
resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

An extraordinary general meeting of SoftOx Solutions AS (the “Company”) was held today on 18 October 2022 at 15.00. The general meeting was held as a video conference meeting. 2 838 164 shares were represented, corresponding to 27,44 % of the Company’s total share capital.

The general meeting approved all the proposals on the agenda in line with the notice dated 11 October 2022.

Signed minutes from the general meeting are attached to this announcement and will be made available on the Company’s website.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
biopharmaceutical and MedTech company based in Oslo, with the goal of reducing
the spread of infection and emergence of antimicrobial resistance. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

→   573355_SoftOx_EGM minutes_norwegian – signed.pdf

→   573355_Appendix 1_voting.pdf
→   573355_SoftOx_EGM minutes_english – signed.pdf

Oslo, Norway, October 11, 2022: Hermod Farms AS, a legal person closely associated with a person discharging managerial responsibilities in SoftOx Solutions AS, CEO Geir H. Almås, has notified the company of participation in the convertible loan announced October 11, 2022.

Please refer to the attached for further information.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftfOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information pursuant to MAR article 7, and is publicly disclosed in accordance with MAR article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biopharmaceutical and MedTech company based in Oslo with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

572933_Skjema for melding om transaksjoner utført av personer med ledelsesansvar (primærinnsidere) og deres nærstående (KRT-1500).pdf

Reference is made to the stock exchange announcement by SoftOx Solutions AS (the “Company” or “SoftOx”) on the 4th of October 2022 regarding, amongst other, the Company’s limited cash position and need for liquidity. On this background, the Board of SoftOx has now raised a new convertible loan from certain existing shareholders who will provide the Company with new liquidity of NOK 25 million, plus a refinancing of the convertible loan of NOK 15 million reported on 28 June 2022. The total proceeds of the new loan will be NOK 40 million and have a due date 15 January 2024.

Together with the previously announced grants on the SoftOx inhalation solutions (SIS), the new loan will secure the Company a liquidity injection of up to a total amount of NOK 50 million. Payment of the funds under the SIS grant is subject to signing the final contract.

Continued pursuit of strategic solutions and partnerships

The new loan will give SoftOx time to deliver on previously announced target milestones over the next 6-9 months. The company has initiated a cost improvement plan to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures and prioritize its ongoing development project. The Company continues to pursue different options to secure long term financing of the Company and is amongst other working on strategic solutions such as licensing out, sale of assets and future collaborating investments relating to the Company’s projects and assets.

“In line with our strategy, both wound care technology for human and animal health care and its disinfection technology, have, with the latest development, all reached a level of the development which opens for strategic partnership talks”, says Almås.

Further, the Company has made a strategic decision to merge the European Defence Fund (EDF) project for military use (preparedness for chemical and biological attacks) and the SIS project for civil use (fighting virus infections). The two projects are based on the same technology and by continuing the development as one merged project, the Company expects that it will benefit from the synergies between the two projects and that it expects to be in position to receive significant public funding for future development through the European Defence Fund program.

The structure of the convertible loan:
1. The loan is NOK 40 million in total, whereof NOK 15 million shall be used to refinance a loan from Almhaug Bolig AS from 28 June 2022. The remaining net proceeds from the loan shall be used for general working capital and corporate purposes.

2. The loan shall carry a fixed yearly interest rate of 10% p.a., to be paid in kind calculated quarterly and will accrue in full at the conversion date or maturity date of the loan.

3. The loan will be secured with sufficient pledge in the Company’s assets (patent portfolio).

4. The loan will run without instalments and the Company shall repay to each lender that lender’s amount of loan outstanding (not converted into Shares) in full on the Maturity Date, the 15th of January 2024, together with all accrued but unpaid interest, costs, and expenses.

5. A lender may at any time up to the Maturity Date convert each lender’s loan amount in full (the “Conversion Amount”) into new shares at the applicable Conversion Price.

6. The Conversion Price shall be NOK 22.5, which is about equal to the WVAP in the five-day period up to and including 7th of October, 2022.

7. The loan is subject to the approval of the Company’s extraordinary general meeting and will be registered in the Norwegian Registry of Business Enterprises in accordance with section 11-6 of the Norwegian private limited companies act.

8.The loan is otherwise on customary terms and conditions for such loan.

Geir Almås, CEO and primary insider of the Company, has through his closely associated company Hermod Farms AS subscribed and been allocated an amount of NOK 2.2 million of the loan. See the attached notification form for persons discharging managerial duties.

The Board has considered the loan in light of the rules on equal treatment under Oslo Rule Book II for companies listed on the Oslo Stock Exchange and the Oslo Stock Exchange’s Guidelines on the rules of equal treatment. The loan implies a deviation from the existing shareholders’ pre-emptive rights to subscribe for and be allocated an amount of the loan. The Board has carefully considered such deviation and has resolved that the loan is in the best interests of the Company and its shareholders. In reaching this conclusion, the Board has among other things considered the availability of capital markets financing in a timely manner together with the necessity for the Company to strengthen its liquidity in the short term. Further, the Board has taken into account that the loan is based on the investor interest obtained following a marketing process with certain existing shareholders, and a public announcement that the Company was seeking funds.

Based on the above, the Board of Directors has decided to propose that the Company’s general meeting resolves the loan in accordance with the Private Limited Companies Act section 11-2 and calls an extraordinary general meeting for approval of the loan.

Notice of extraordinary general meeting
Notice is hereby given of an extraordinary general meeting of Company to be held on 18 October 2022 at 15:00 hours (CEST) in the offices of the Company in Oslo. The meeting will be a physical event, with the opportunity to attend the meeting online on request. The notice to the extraordinary general meeting and proxy forms and appendices are attached and are also available at www.soft-ox.com.

SpareBank 1 Markets is acting as financial advisor to the Company in connection with the issuance of convertible loan.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Mundal Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biopharmaceutical and MedTech company based in Oslo with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

572916_SoftOx Solutions – Styrets redegjørelse – ASL §3-8.pdf

572916_SoftOx Solutions – EGM notice.pdf

SoftOx Solutions AS (“SoftOx” or the “Company”), a clinical-stage biopharmaceutical company, with a separate disinfection branch in Norway, has
received the Swedish Chemicals Agency’s final product assessment draft for the SoftOx disinfection family. SoftOx has reviewed the report and notified the Agency that the company fully supports it. The next step is a final decision on the application for SoftOx’s hand- and surface disinfectants.

With an approval from the Swedish Chemicals Agency, SoftOx can apply for mutual recognition in sequence in any EU market, including Norway. Furthermore, in parallel and in line with the company’s strategy, SoftOx will initiate talks with several potential distributors and disinfection players to bring the company’s competitive disinfection technology to market both in Europe and internationally.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biopharmaceutical and MedTech company based in Oslo with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

– The SoftOx Biofilm Eradicator (SBE) was shown to be safe and well tolerated.
– Treatment with SBE consistently reduced bacterial burden in chronic leg ulcers.
– The SBE-01 study demonstrates further proof-of-concept for the company’s wound care technology platform.
– SoftOx wound care formulations tailored to treatment of wounds in the presence or absence of biofilms.

OSLO – October 4, 2022
SoftOx Solutions AS (“SoftOx” or the “Company”), a clinical-stage biopharmaceutical company based in Norway, announces top line results from its Phase 1 clinical study evaluating the safety and tolerability of SoftOx Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx’s antimicrobial solution for the treatment of chronic wounds. In addition, the company provides an update on its financial situation.

“A large proportion of chronic wounds, like venous leg ulcers and diabetic foot ulcers, are colonised by multiple species of bacteria organised in biofilms. These biofilms are detrimental to the wound healing process and are difficult to treat with conventional antiseptics and antibiotics,” says Dr Christopher Burton, Chief Medical Officer of SoftOx. “The SBE formulation has been specifically designed to penetrate the biofilm and exhibit an antimicrobial effect throughout the wound bed, to improve subsequent wound healing. The results of the SBE-01 trial are another important step towards realising a product that is expected to greatly improve quality of life for a large group of people suffering from chronic wounds of variable causes.”

SBE-01 is a first-in-human study investigating the safety, tolerability, and antimicrobial efficacy of single and multiple doses of SBE in patients with chronic leg wounds. The Phase 1 study was divided into two parts: a randomized, blinded, Single Ascending Dose (SAD) phase, followed by an open label, Multiple Ascending Dose (MAD) phase, where patients were treated once-daily or twice-daily over five days.

Data from the SBE-01 study demonstrate that SBE was safe and well-tolerated. There were no statistically significant differences in the evaluation of pain during and after the wound cleaning procedure comparing SBE with placebo. Treatment with all SBE formulations consistently reduced the absolute number of bacteria (bacterial burden) in the wound compared with pre-treatment (baseline). A dose dependent reduction in wound size was also observed in the multiple dose SBE treatment groups.

“These positive results add to our growing body of clinical evidence supporting the company’s wound care technology platform. There are around 40 million people with chronic wounds worldwide, where drug and medical device treatment costs are estimated to be $600 for each infection. The SoftOx technology promises to be a cost-effective wound care treatment, that can also be an effective solution to the treatment of multidrug-resistant bacteria, such as Methicillin Resistant Staphylococcus Aureus or MRSA,” said Geir Almås, CEO of SoftOx. “Moving forward, we are excited to explore potential strategic partners to advance this promising asset through the clinical development.”

Proof of concept
The SoftOx technology platform is highly versatile, new generation antimicrobial agent with the potential to treat different types of wounds, from infection prevention in acute surgical or non-surgical wounds to infection removal in wounds typically associated with biofilm such as chronic leg ulcers and traumatic penetrating injuries.

SoftOx has previously published clinical data supporting the association between the use of SoftOx technology and improved wound healing in acute wounds. Taken together with the results from the SBE-01 study of antimicrobial effects in chronic leg wounds over a safe and tolerable dose range, these combined results are early proof of concept for the SoftOx wound care technology platform for a range of potential acute and chronic wound care indications.

Klaus Kirketerp-Møller, MD, PhD, from Copenhagen Wound Healing Center at Bispebjerg Hospital, Denmark commented: “We are encouraged by these results, which speak to the potential of SBE as a treatment of chronic wounds as well as aiding in the fight against antimicrobial resistance as a possible alternative to antibiotics.”

Significant unmet need
Combination antibiotic therapy and physical removal of biofilms are the commonly used forms of treatment of biofilm-associated infections today, but there remains a significant unmet need for new and innovative approaches to tackling biofilm and multidrug-resistant bacteria. Previous studies have shown that antimicrobial-resistant bacteria are present in more than 50 per cent of chronic wounds. According to the World Health Organization (WHO), antimicrobial resistance is one of the largest threats to human health. In 2019 alone, antimicrobial-resistant bacteria contributed to 4.95 million deaths worldwide.

Next steps
Having demonstrated early proof of concept for the SBE project and in accordance with the company’s corporate strategy, SoftOx will seek a strategic partner to further develop and advance its wound care segment within acute and chronic indications.

The clinical development of SBE is co-funded by the US Naval Medical Research Center (NMRC) through the Medical Technology Enterprise Consortium (MTEC), a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command.

For more information about the study, please visit the European Union Drug Regulating Authorities Clinical Trials Database and reference identifier: EudraCT no. 2021-000314-42.

About biofilm and antimicrobial resistance
Biofilm in chronic wounds is a cluster of bacteria covered by a matrix, which makes it difficult for today’s antibiotics to effectively eradicate the
infection in chronic wounds. Up to 2 per cent of the population of developed countries are projected to experience a chronic wound during their lifetime. Within organised biofilms, bacteria are more resistant to antibiotics and the immune responses, making clinical treatment of biofilm infection difficult. According to the WHO, antimicrobial resistance is considered as a global crisis that threatens a century of progress in health. Presently, deaths linked to multidrug-resistant bacteria are already higher than those related to HIV/AIDS or malaria.

Update on the company’s financial situation
As reported at the end of the previous quarter, the company has a limited cash position, and there is a need to financially strengthen the company and its liquidity in the short and long term. The company is working actively with different solutions in this respect, both financially and strategically. Amongst others, the proof-of-concept data for the SBE are expected to play a vital role in securing future partnering investments and collaborations, and if successful, the company believes that a sale or partnership will provide the company with a good foundation to support the company’s financial situation and activities in the long term.

To strengthen the liquidity situation in the shorter term, the company has initiated a cost improvement plan to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures and prioritize its ongoing development projects. On the basis of this plan, the company estimates that a cash injection of up to NOK 50 million is sufficient to fund the company to June 2023. An underwritten rights issue is one of the alternatives being evaluated. The estimated capital need does not take into account that approximately NOK 25 million of the previous announced grants on the SoftOx inhalation solution (SIS) is expected to be pre-paid at the time of signing the research agreement (as SoftOx is defined as a SMB company).

The company will provide an update as soon as a solution has materialized and thus also indicate the financial and accounting effects on the same.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Christopher Burton, CMO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information pursuant to MAR article 7 and is publicly disclosed in accordance with MAR article 17. The announcement is made by the IR responsible.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biopharmaceutical and MedTech company based in Oslo with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com

References:
MedMarket Diligence (2011). Wound prevalence and wound management: 2012-2020

MedValue & Radboud University (2019). Decision Modeling Assessment.

IACG (2019). No Time to Wait, WHO. https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1

https://www.ox.ac.uk/news/2022-01-20-estimated-12-million-people-died-2019-antibiotic-resistant-bacterial- infections#:~:text=First%20comprehensive%20analysis%20of%20global,role%20in%204.95%20million%20deaths.

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based in Norway, announced today the end of the Phase 1 clinical study of the SoftOx Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx’s antimicrobial solution for treatment of chronic wounds.

“We would like to thank our study participants and the staff at DanTrials ApS. SoftOx is looking forward to announcing the top line results in Q4 2022,” said Glenn Gundersen, Sr Medical Director of SoftOx.

SBE-01 is a first-in-human study investigating the safety, tolerability, and antimicrobial efficacy of single and multiple doses of the SoftOx Biofilm Eradicator (SBE) in patients with venous leg ulcers. In Phase 1b the company treated the wounds once and twice daily over 5 days. The original study design included three times daily administration for five days; however, the company expects that data from the two first groups are sufficient to document safety, tolerability, and antimicrobial efficacy in clinically relevant treatment schedules in chronic wounds.

“With the closure of Phase 1 study, we can turn our attention towards analysing the data and complete our preparations for the Phase 2 study investigating the effect of SBE on wound closure in venous leg ulcers,” said Gundersen.

Co-funded by the US Naval Medical Research Center
The study is co-funded by the US Naval Medical Research Center (NMRC) under the Medical Technology Enterprise Consortium (MTEC), a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command.

“The Phase 2 study will also be co-funded by the United States Naval Medical Research Center, and we are confident that the SBE-01 results will support selection of an optimal SBE formulation and dosing schedule for treating patients with chronic wounds in both hospital and long-term community care settings,” said Gundersen.

SBE is in clinical development as an anti-infective treatment for chronic wounds, designed specifically to penetrate and kill pathogens within biofilms. Due to the broad spectrum and multi-targeted antimicrobial effects, SBE has been shown to kill antibiotic resistant bacteria in biofilms without inducing new antimicrobial resistance in vitro. SoftOx has previously published clinical data supporting the association between reduced bacterial burden and improved wound healing. These associations will be further investigated in the planned SBE Phase 2 (SBE-02) study.

As previously reported, SBE-01 recruitment was delayed in the early stages of the trial due to the Danish nursing strike in 2021. To maintain overall clinical development timelines, SoftOx has taken the decision to omit the three times daily treatment, stop further patient recruitment and to end the trial.

Facts about biofilm:
Biofilm in chronic wounds is a cluster of bacteria covered by a matrix, which makes it difficult for today’s antibiotics to effectively eradicate the infection in chronic wounds. 1-2 % of the population are projected to experience a chronic wound during their lifetime in develop countries. Under the protection of biofilm, microbial cells in biofilm become tolerant and resistant to antibiotics and the immune responses, which increases the difficulties for the clinical treatment of biofilm infection.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Senior Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – September 1, 2022 – SoftOx Solutions AS (“SoftOx” or the “Company”), a clinical-stage pharmaceutical and medtech company based in Norway, strengthens its leadership team in SoftOx Defense Solutions AS (SDS), a subsidiary of SoftOx, with the appointment of Jørgen Berggrav as Senior Advisor and Johan Christian Harstad as the Project Director. The appointments will take effect, as of today September 1, 2022. ‘

In addition, Chief Executive Officer of SoftOx Solutions AS, Geir Almås, will act as interim CEO of SDS, succeeding Rune Jomaas, until a suitable successor has been identified.

Geir Almås, Chief Executive Officer of SoftOx Solutions, commented: “I’m delighted to welcome both Berggrav and Harstad to the SoftOx team as this exciting time. Their expertise and knowledge from the international and national military sector will strengthen the SoftOx team and support SDS’s work for the European Defence Fund as we continue our close collaboration with Norwegian Defence Research Establishment (FFI)”.

On the 20th of July 2022, SoftOx announced that SDS was granted NOK 97 million from the European Defence Fund (EDF). This funding will contribute to the development of a MCM inhalator based on the SoftOx technology. The goal is to give military forces and civilians an effective countermeasure against chemical, biological, radiological and nuclear (CBRN) threats.

Jørgen Berggrav graduated from the Royal Norwegian Naval Academy (Sjøkrigsskolen) and has served in the submarine force as a ship’s officer, ship’s commander and operations and training officer. Berggrav has held many diverse roles in the Armed Forces including as Director General in the Ministry of Defence, representative of Europe to the Supreme Allied Commander Transformation and representative of the Chief of Defence at NATO’s operational command, SHAPE, commander of the Landsdelskommando Nord-Norge, and staff training at the Bundeswehr Command and Staff College (die Führungsakademie der Bundeswehr) in Germany, the Armed Forces Academy, and Defence Attaché in Finland. In addition, Berggrav has been Chief Principal for HM the King and was appointed rear admiral in 2003. Following his retirement, Berggrav was the Secretary General of the Norwegian Reserve Officers’ Federation for nearly eight years.

Johan Christian Harstad is a former submarine commander, and his last position was as deputy leader in the Norwegian Special Operation Forces with the rank of Commodore. Harstad has international experience with the United States Special Operations Command in experimentation and restructuring of military capabilities. He also studied security policy and foreign relations at the US Naval War College. Harstad has served in the Norwegian Armed Forces’ central staff in Oslo and worked for four years in the Ministry of Defence.

Berggrav and Harstad’s focus will be to further develop the SoftOx applications to strengthen the military and civilian preparedness against future epidemics, chemical and biological warfare, complex wound infections and challenging conditions in the respiratory tract.

More details regarding the European Defence Fund grant and project are available at the company’s webpage
(https://soft-ox.com/2022/08/30/the-european-defence-fund-grant-the-project-and-future-opportunities/).

For further information, please contact:
Geir Almås, Chief Executive Officer SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx), listed on Euronext Growth Oslo, is a Norwegian
pharmaceutical/medtech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR),biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – August 15, 2022: SoftOx Solutions AS (“SoftOx” or the “Company”), a clinical-stage pharmaceutical and medtech company based in Norway, today announces its results for the second quarter and first half year of 2022.

“Over halfway into 2022, I am proud to report on the significant progress made in our clinical and commercial development, such as demonstrating proof of concept and identifying the best partners to advance our pipeline,” said Geir Almås, CEO of SoftOx.

The first half of 2022 has been characterized by increased clinical trials and regulatory activities. In July, SoftOx announced the positive feedback on it’s European Defence Fund (EDF) application and the award of approximately NOK 97 million to develop a military inhalation solution for the European Union and its allies. The SoftOx technology and team have been carefully selected by the EU commission to develop medical countermeasures to certain threats is a testament the company’s to expertise in the field.

“Moving forward, we remain focused on delivering on our ambitious goals, advancing the clinical development and finding the right partners for our projects,” Geir Almås concluded.

Operational highlights

• Through SoftOx Defense Solutions, SoftOx was granted approximately NOK 97 million from the European Defence Fund to develop an inhalation solution for the armed forces within the EU and its allies.
• In May, SoftOx announced that the Phase 1 study, SIS-01, which evaluated the safety and tolerability of the SoftOx Inhalation Solution, had met its primary objective in healthy subjects (NCT05188638).
• SoftOx submitted a Premarket Notification to obtain clearance by the US Food and Drug Administration for the SoftOx Wound Irrigation Solution (SWIS) to be used as a Class II medical device in the US.
• The Norwegian Defence Research Establishment (FFI) ‘s field experiment in Hemsedal evaluating non-alcohol disinfectants, including SafeDes+, SoftOx’s alcohol-free hand disinfectant, showed that alcohol-free disinfectants reduced the level of volatile organic compounds (VOCs) in the air when compared with alcohol disinfectants.
• In May, SoftOx presented the results of the SWIS-02 study and hosted a symposium entitled “Future practical solutions for fighting antimicrobial resistance in wound care” at the European Wound Management Association conference in Paris.
• The positive results of the SWIS-02 study demonstrating improvement in wound healing and reduction in bacterial burden compared to Normal Saline were published in the peer-reviewed journal, Acta Dermato- Venereologica

Financial highlights
(Figures in brackets represent the corresponding period in 2021 unless states otherwise)

• Pre-tax results amounted to a loss of NOK 20.6 million in the second quarter (loss of 21,3 million)
• Total operating expenses for the second quarter were NOK 21.5 million (NOK 23.8 million)
• Cash and cash equivalents amounted to NOK 7.4 million at the end of the second quarter (NOK 31.1 million)
• In June, SoftOx entered into a NOK 15 million loan agreement with Almhaug Bolig AS, where the main shareholder is one of the shareholders in SoftOx

Presentation details
The results will be released at 07:00 (CET) on Monday, August 15th, 2022 and presented by the management at 10:00 (CET) at SpareBank 1 Markets, Olav V’s gate 5, Norway.

The presentation is open to the public and can also be followed via the link:
https://channel.royalcast.com/landingpage/hegnarmedia/20220815_2/

The presentation will be held in English and followed by a Q&A session.

Please register for the event before August 15th, at 08:00 (CET), by sending your registration to corporateaccess@sb1markets.no

For any questions or interview requests, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com Phone:
Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

  568533_Q2 FINAL 14.08.2022.pdf

SoftOx Solutions AS is pleased to invite investors, analysts and other stakeholders to our extended 2Q 2022 results presentation on Monday August 15th, 2022. The event will be held in-person as well as being streamed live. The interim report and related materials will be made available on
https://soft-ox.com/financial-calendar-reports/.

The 2Q 2022 results will be released at 07:00 (CET) on Monday August 15th, 2022 and will be presented by the management at 10:00 (CET) at SpareBank 1 Markets, Olav V’s gate 5, Norway. The presentation is open to the public and can also be followed via the link:
https://channel.royalcast.com/landingpage/hegnarmedia/20220815_2/

The presentation will be held in English and followed by a Q&A session. Please register for the event before August 15th, at 08:00 (CET), by sending your registration to corporateaccess@sb1markets.no

For any questions or interview requests, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS is pleased to invite investors, analysts and other stakeholders to our extended 2Q 2022 results presentation on Monday August 15th, 2022. The event will be held in-person as well as being streamed live. The interim report and related materials will be made available on
https://soft-ox.com/financial-calendar-reports/.

The 2Q 2022 results will be released at 07:00 (CET) on Monday August 15th, 2022 and will be presented by the management at 10:00 (CET) at SpareBank 1 Markets, Olav V’s gate 5, Norway. The presentation is open to the public and can also be followed via the link: https://channel.royalcast.com/landingpage/hegnarmedia/20220815_2/

The presentation will be held in English and followed by a Q&A session.
Please register for the event before August 15th, at 08:00 (CET).

For any questions or interview requests, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Financial calendar for SoftOx Solutions AS

FINANCIAL YEAR 2022

15.08.2022 – Half-yearly Report
03.04.2023 – Annual Report
17.04.2023 – Annual General Meeting

26.10.2022 – Quarterly Report – Q3
17.02.2023 – Quarterly Report – Q4

This information is published pursuant to the requirements set out in the Continuing obligations.

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based in Norway, announced today the positive feedback for its subsidiary company, SoftOx Defense Solutions (SDS) on its European Defence Fund (EDF) application. SDS has been granted approximately NOK 97 million to develop an EU military inhalation solution for all EU military troops.

SDS announced December 12, 2021, the submission of the EDF application with a pan-European consortium, consisting of 20 international research and development (R&D) and industry partners from 10 nations. The consortium, led by Commissariat a l’Energie Atomique et aux Energies Alternatives (CEA) in France, is developing military medical countermeasures (MCMs) against chemical substances, biological agents, radioactive and nuclear substances, so-called CBRN substances, for use in the Norwegian Armed Forces and the EU’s military forces.

The consortium is granted approximately NOK 500 million and SDS is assigned 20 percent of these R&D-funds, which will be allocated at the end of 2022 for 3 years onwards. The Norwegian Ministry of Defence (FD) and SoftOx will jointly cover approximately 10 % of the awarded funding and FD has guaranteed to additionally co-finance 40% of the Norwegian contribution.

The EDF incentivises and supports collaborative, cross-border R&D in the area of defence. The Fund aims to increase the EU’s technological edge and develop capabilities key for strategic autonomy and resilience for its Member States and the protection of its citizens. To increase the resilience against these emerging threats, intended accidental or natural origin, it is critical that Europe develops necessary capabilities to protect its military and civilian population through MCMs for which today very few are approved for use. The present EDF grant seeks to enhance preparedness in CBRN security and emphasizes the urgency to improve preparedness for and response to CBRN threats through the development of appropriate MCMs.

“We are honoured and extremely proud to have been accepted as an important and integral player in this pan-European consortium and grateful for such significant funding for our research and development plans”, said Rune Jomaas, CEO of SDS. “This grant is unique in a Norwegian industry context and was made possible thanks to the support and close cooperation with the Norwegian Ministry of Defence (FD), the Norwegian Defence Research Establishment (FFI) and the Norwegian Defence and Security Industry Association (FSi). With this grant, SDS will proceed into a contractual phase preparing for an exciting pan-European research activity with dedicated partners”, concluded Jomaas.

“These funds will ensure collaboration and partnerships with leading European research institutions with a common goal to develop new and advanced technology against CBRN threats. This synergy will be instrumental and invaluable for SDS and SoftOx for advancing the SoftOx technology platform into new products as MCMs for the European defence market”, said Glenn Gundersen, Medical Director of SDS and SoftOx.

Geir Almås, CEO of SoftOx, added, “This funding is a significant recognition of our effort to develop cutting-edge technology. The grant also confirms that the SoftOx technology platform can potentially be a significant game-changer in developing new medical solutions for both the civilian and military market.”

For further information, please contact:
Geir Almås, Chief Executive Officer SoftOx Solutions AS or
Rune Jomaas, Chief Executive Officer SoftOx Defense Solutions AS
Glenn Gundersen, Medical Director, SoftOx Solutions AS/SoftOx Defense Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information pursuant to MAR article 7 and is publicly disclosed in accordance with MAR article 17. The announcement is made by the IR responsible.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx), listed on Euronext Growth Oslo, is a Norwegian
pharmaceutical/medtech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based in Norway, announces the publication of data from a randomized control trial (RTC) evaluating the wound-healing effect of SoftOx’s stabilized hypochlorous acid solution (HOCl) on acute wounds. The results were published in Acta Dermato-Venereologica, a peer-reviewed journal focused on clinical and experimental research in dermatology and venerology.

The randomized trial applied a suction blister wound model and randomized 20 healthy volunteers whereby stabilized hypochlorous acid or control (saline) solutions were assigned. The study’s primary objective was to evaluate the wound healing properties of HOCI, and the secondary objective was microbiological control, pain levels and safety with stabilized HOCl compared to the control treatment.

Wounds were treated and rinsed on days 0, 2 and 4. Wound healing was assessed blindly, and bacterial growth was evaluated as the number of colony-forming units cultured from surface swabs.

Stabilized HOCI was found to accelerate early re-epithelialization (wound healing) significantly on day 4 compared with the control group (p=0.00051) and was not inferior to the control solution on day 10 (p<0.0001). In addition, the median bacterial counts in the wounds were significantly lower after treatment with stabilized HOCI compared with the control group directly after treatment, which also lasted over time.

Overall, the study demonstrates the immediate and durable antimicrobial action and beneficial effect of stabilized HOCI on acute wounds and suggests that hypochlorous acid is a promising antimicrobial wound rinsing agent.

The full title of the publication is: Effect of Stabilized Hypochlorous Acid on Re-epithelialization and Bacterial Bioburden in Acute Wounds: A Randomized Controlled Trial in Healthy Volunteers” and can be accessed here:
https://medicaljournalssweden.se/actadv/article/view/1624

Co-author and medical director of SoftOx Solutions Glenn Gundersen, commented:

“We are encouraged by these data, which demonstrate the potential of stabilized hypochlorous acid as a well-tolerated wound irrigation device with significant antimicrobial properties. We know that the overuse or misuse of antibiotics is linked to the emergence of antimicrobial resistance, so it is crucial to identify new and effective treatments to prevent and treat wound infections without inducing resistant microbes. “

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

The Board of SoftOx Solutions AS (the “Company”/”SoftOx”) has entered into a loan agreement with Almhaug Bolig AS, where the main shareholder is one of the shareholders in SoftOx. Almhaug Bolig AS will provide the company with a short-term loan of NOK 15 million.

The Company has experienced some delays both in connection with regulatory and commercial processes and in the implementation of certain clinical studies. To compensate for the liquidity burden caused by these delays, the company’s main shareholder has given the company a loan of NOK 15 million.

The Company is considering increasing the amount of the Loan to up to approx. NOK 30 million to be raised from existing shareholders and certain professional investors, subject to a minimum individual loan amount of NOK 1 million.

The net proceeds of the Loan will be used to fund the Company’s ongoing project and operating activities and for general corporate purposes.

Almhaug Bolig AS has committed to NOK 15 million of the Loan, of which NOK 5 million will be in form of refinancing of the convertible loan raised in October 2021 and the remaining NOK 10 million will be in cash. Almhaug Bolig AS is a shareholder of the Company, in which the Company’s ultimate main shareholder is also a shareholder and chair of the board.

The Loan does not accrue any interests and the loan falls due 15 January 2024. The individual lenders may convert the outstanding amount of the Loan into shares in share capital increases with issuance of new shares in the Company and set off of the lenders’ claim for repayment of the Loan at any time prior to maturity. The conversion price will be calculated based on a volume weighted average trading price for the Company’s shares prior to the Loan less 10%, provided, however, that if the Company carries out a share offering at a price lower than the conversion price, the lender will have the right to convert the loan at the lower price in such offering shall apply.

Any new shares to be issued pursuant to the conversion right under the loan agreement will be resolved by the Company’s board of directors pursuant to the authorization granted by the Company’s annual general meeting on 12 May 2022 to increase the Company’s share capital (or any other authorization available to the board of directors at such time).

The Board has considered alternative structures for raising funds. Following careful considerations, the Board is of the view that it will be in the common interest of the Company and its shareholders to raise funds through the convertible loan setting aside the pre-emptive rights of the shareholders. By structuring the funding as a convertible loan, the Company will be in a position to raise capital before the summer, and in an efficient manner, with a lower discount to the current trading price and with significantly lower risks compared to a rights issue.

The Company expects that it will seek to raise additional funds during the next 12 months and will then seek to structure such offering in line with market practice for capital raising, subject to prevailing market conditions.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information
pursuant to article 7 of the Market Abuse Regulation, and is publicly disclosed
in accordance with article 17 of the Market Abuse Regulation and section 5-12 of
the Norwegian Securities Trading Act. The announcement is made by the contact
person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based in Norway, notes the Norwegian Defence Research Establishment’s (Forsvarets Forskningsinstitutt (FFI)) field experiment evaluating non-alcohol disinfectants, including SafeDes+, SoftOx’s alcohol-free hand disinfectant, in comparison with alcohol-based disinfectants.

The field experiment took place in Hemsedal, Norway and collected data from 175 indoor air quality sensors to assess the importance of air quality and employees’ ability to perform assigned tasks.

According to the report, alcohol-free disinfectants reduced the level of volatile organic compounds (VOC) in the air during the intervention period by 30-60% when compared with alcohol disinfectants.

The data also represent a statistically significant association between reported long-term sick leave, VOC and temperature, which are relevant to employee performance and well-being.

Additional analysis shows that employees experienced a better indoor environment and well-being during work hours when using non-alcohol disinfectant products.

FFI’s article (in Norwegian) on the experiment and its main findings can be accessed via the following link:

https://www.ffi.no/aktuelt/nyheter/tester-ut-alkoholfri-desinfisering-for-forsvaret 

The full FFI report (in Norwegian) can be accessed via the following link:
https://www.ffi.no/publikasjoner/arkiv/kan-alkoholfrie-desinfeksjonsprodukter-st
yrke-forsvarets-operative-evne

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian medtech/biotech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – May 19, 2022: SoftOx Solutions AS (“SoftOx” or the “Company”), a clinical-stage pharmaceutical and medtech company based in Norway, today announced top line results from its Phase 1 study evaluating SoftOx Inhalation Solution (SIS). SIS is a novel aqueous formulation of hypochlorous acid (HOCl), a biological oxidant with broad spectrum antimicrobial (antiviral and antibacterial) properties.

In this Phase 1, first-in-human study, nebulised SIS achieved the primary objective of safety and tolerability in healthy subjects. There were no observed local tolerability issues, no adverse effects on pulmonary function, and no serious adverse events.

“We are highly encouraged by these Phase 1 results demonstrating an acceptable safety and tolerability profile for a potential future inhaled antiviral treatment”, says Dr Christopher Burton, Chief Medical Officer for SIS. “This study paves the way forward for the future clinical development of SIS within infectious disease indications in the upper and lower respiratory tract.”

SIS-01 is a first-in-human study investigating the safety and tolerability of single and multiple ascending doses of nebulised SIS to healthy subjects. The randomized, double-blind trial was the first systematic, placebo-controlled study investigating the safety and tolerability of inhaled HOCl in humans. A total of 57 healthy volunteers were randomised to receive SIS formulations of up to 100 µg/ml HOCl, four times daily for five days, or a matching placebo regimen.

“SIS has the potential to be a breakthrough in respiratory treatment”, stated CEO Geir Almås of SoftOx, “the broad spectrum antimicrobial effect of SIS obviates the need for expensive diagnostic testing which can also delay the start of treatment, and would represent a paradigm shift in the management of respiratory infections.”

Data from the study demonstrates that an aqueous formulation of HOCl can be administered to the respiratory tract as an aerosol, as evidenced by dose-response effects on safety parameters, which were predominantly mild, even in the most intensive dosing regimen.

With these positive results from the Phase 1 study, SoftOx will continue Phase 2 clinical development of SIS. The company is already in the process of preparing Phase 2 documentation and is engaged in dialogue with the European Medical Association.

For more information about the SIS-01 study, please visit clinicaltrials.gov and reference identifier: NCT05188638.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Christopher Burton, CMO, SIS, SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information pursuant to MAR article 7 and is publicly disclosed in accordance with MAR article 17. The announcement is made by the IR responsible.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
pharmaceutical/medtech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical and medical technology company based in Norway, announces that it will attend and host an educational symposium at the European Wound Management Association (EWMA) Conference in Paris, France, from 23-25 May 2022.

The European Wound Management Association (EWMA) is a European not-for-profit umbrella organisation, linking national wound management organisations, individuals and groups with interest in wound care. EWMA was established in 1991 as a charity organisation registered in the UK.

The EWMA is focused on supporting the implementation of interdisciplinary and cost effective wound care of high quality. EWMA works to reach its objectives by being an educational resource, organising conferences, contributing to international projects related to wound management, actively supporting the implementation of existing knowledge within wound management, and providing information on all aspects of wound management.

SoftOx will be hosting a symposium titled ‘Future practical solutions for fighting antimicrobial resistance in wound care’, which will take place on Wednesday, 25 May 2022, from 12.15-13.15 CEST.

“Microbial resistance is one of the most major threats to human health. Navigating this challenging field of research, we are excited to host a symposium homing in on how we manage antimicrobial resistance in wound care and, importantly, promising and cutting-edge research,” said Geir Almås, CEO SoftOx Solutions AS.

At the Joint EWMA & Journées Cicatrisations Conference, SoftOx will be an exhibitor and presenter. The SWIS-02 study has been selected for oral presentation by its principal investigator, and CEO Geir Almås will present on the EXCITE International approach and participate in a meet-the-experts session as an EXCITE International advisory council member.

Symposium details:

Title: Future practical solutions for fighting antimicrobial resistance in wound care
Date and time: Wednesday, 25 May 2022, 12:15 – 13:15 hrs

Speakers and agenda:

• Prof. Niels Frimodt-Møller (Rigshospitalet, Dept. of Clinical Microbiology, Copenhagen, DK)
Antimicrobial resistance in your practice: an ever more powerful adversary

• Prof. Thomas Bjarnsholt (Copenhagen University Hospital, Dept. of Clinical Microbiology, Copenhagen, DK)
Countering antimicrobial resistance: its history and mechanism of action

• Dr. Klaus Kirketerp-Møller (Wound Healing Center, Bispebjerg University Hospital, Copenhagen, DK)
Fighting antimicrobial resistance in wound care tomorrow: clinical research today

Chair: Geir Almås, CEO SoftOx Solutions AS

A recording of the symposium will be made available on the Company’s website at https://soft-ox.com/investor-presentations/.

For further information, visit the EWMA conference website here: https://ewma.org/ewma-conferences/2022

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
biotech/medtech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses.
For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS will be holding its Annual General Meeting on 12 May 2022 at 12:00 hours (CEST).

The notice convening the general meeting, including the agenda and the board’s proposals to the matters to be dealt with, is enclosed with this notification and will be sent to all shareholders.

Relevant documents referred to in the notice are also made available on
https://soft-ox.com/press-releases-updates/

For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm  infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

→ 561276_Notice of Annual General Meeting 2022_SoftOx Solutions AS in pdf

→ Articles of association 2022_SoftOx Solutions AS in pdf

→ Guidelines for remuneration 2022_SoftOx Solutions AS in pdf

→ Nomination committee recommentations 2022_SoftOx Solutions AS in pdf

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based in Norway, announces that it has published its Annual Report for 2021. The Board of Directors has approved the 2021 annual financial statements prepared in accordance with the Norwegian Accounting Act and accounting standards and practises generally accepted in Norway. The financial statements are in accordance with the Q4 reporting published on 16th February 2022.

“We look back on 2021 as the year of the formal validation of our technology in clinical trials and in the healthcare sector. This is the beginning of a breakthrough for the prevention and treatment of infections “, says CEO Geir Almås of SoftOx. “2021’s successes far outweighed the challenges, and we are
closer than ever to achieving our goals of sharing a new class of antimicrobials. The global attention on viruses and antimicrobial resistance
confirms the need for what we have been working on for years – a new solution to fight infections.”

Attached to this notice are the Company’s annual accounts for the financial year 2021, including the financial statements, annual report for the financial year
2021, and auditor’s report.

These documents are also available at the Company’s website,
https://soft-ox.com/press-releases-updates/.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

→ Q1 Report in pdf

The first quarter 2022 report will be available at https://soft-ox.com/financial-calendar-reports/ and attached.

At 10:00 CET, the management will host a webcast to present the results. Following the presentation, there will be a Q&A session where written questions can be submitted to ir@soft-ox.com.

The webcasted presentation will be in Norwegian. To join, please use the link that is available at https://soft-ox.com/investor-presentations/.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

→ Q1 Report in pdf

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based in Norway, announces the completion of last subject last visit in a Phase 1 study of SIS-01 (NCT05188638). SIS-01 is a first-in-human study investigating the safety and tolerability of single and multiple doses of nebulised SoftOx Inhalation Solution (SIS) delivered via a jet nebuliser to healthy subjects. A total of 57 healthy volunteers were randomised to receive SIS or placebo. SoftOx is looking forward to announcing the top line results by the end of Q2 2022.

“We are pleased to report the achievement of this import milestone. We are extremely grateful to our study participants and DanTrials ApS for helping us to complete the study according to plan,” said Dr Christopher Burton, Chief Medical Officer on the SIS project. “We anticipate that this study will provide evidence of a safety and tolerability profile suitable for progression to Phase 2 clinical development within various upper and lower respiratory tract infectious disease indications.”

SIS is a novel aqueous formulation of hypochlorous acid (HOCl), a biological oxidant with broad spectrum antimicrobial (antiviral and antibacterial) properties. This randomized, double-blind trial is the first systematic, placebo-controlled, ascending dose study investigating the safety and tolerability of low concentrations of inhaled HOCl in humans.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Christopher Burton, CMO, SIS, SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biotech/medtech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses.

For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

The fourth quarter 2021 report will be available at https://soft-ox.com/financial-calendar-reports/ and attached.

The webcast presentation by management will take place Monday 28th February 2022, at 13:00 (CET).

Date: Monday, 28th February
Time: 13:00 – 14:00
RSVP: Registration to corporateaccess@sb1markets.no

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Link to Q4 report:

https://soft-ox.com/wp-content/uploads/2022/02/Q4-report-2021_FINAL_15022022.pdf

With reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on 8 February 2022, the webcast presentation, due to take place on 16
February 2022, has been postponed due to Covid among the management. The Q4 2021 results will be made available on www.soft-ox.com and www.newsweb.no on Wednesday, 16 February 2022.

The webcast presentation by management will take place Monday 28th February 2022, at 13:00 (CET).

Date: Monday, 28th February
Time: 13:00 – 14:00
RSVP: Registration to corporateaccess@sb1markets.no

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solution AS will be announcing its results for 4Q 2021 on Wednesday 16th February 2022. A webcast presentation by the management will take place at 10:30 am CET.

Date: Wednesday, 16th February
Time: 10:30 – 11:30
RSVP: Registration to corporateaccess@sb1markets.no

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx vil beholde sitt produkt for hånd og overflate desinfeksjon i markedet. Selskapets uenighet med Miljødirektoratet dreier seg ikke om produktets kvaliteter, men hvorvidt vi har rett til å være i det norske markedet, frem til endelig formell produktgodkjennelse.

Med henvisning til børsmelding 28.1.2022, hvor SoftOx Solutions AS (SoftOx) opplyser at Miljødirektoratet opprettholder sin tolkning av det europeiske biocidreglementet. Dette gjør de til tross for at det ikke er i overensstemmelse med EU kommisjonens (DG SANCO) tolkning av EUs biocidforordning. Miljødirektoratets brev er en tolkningsuttalelse og SoftOx vil, inntil annet blir pålagt dem, forholde seg til EU kommisjonens tolkning av anvendelsesområdet for overgangsordningen og beholde sitt produkt for hånd og overflatedesinfeksjon i markedet. Selskapet har en forventning om at Miljødirektoratet vil legge til grunn samme tolkning av EU regelverket som EU kommisjonen og vil derfor forfølge saken mot norske myndigheter for å få avklart anvendelsesområdet til gjeldende overgangsordning i Norge, herunder endelig avgjørelse på klagesaken i Klima og miljødepartementet. Dersom dette ikke fører frem, vil Selskapet gå til rettslige skritt for å beskytte sine interesser og søke å få en avklaring av regelverket av riktig nasjonal eller internasjonal rettsinstans.

Det er anvendelsen av SoftOx hånd- og overflatedesinfeksjonsproduktet som hånddesinfeksjon, Miljødirektoratet mener ikke er omfattet av en overgangsordning. Produktet er for øvrig godkjent av Statens Legemiddelverk for bruk på overflater i helsevesenet, og valgt av Sykehusinnkjøp som alkoholfri hånddesinfeksjon til norske sykehus for perioden 2022-2026. Produktet er klinisk veldokumentert med fire kliniske studier og en rekke dyrestudier. Samtidig har selskapet med godkjennelse fra Danish Medical Agency igangsatt studier som innebærer bruk av høyere doser i kroniske sår og inhalasjon i lunger av tilnærmet tilsvarende produkt. Virkestoffet i produktet er godkjent av norske myndigheter, vært gjennom en streng risikovurdering og blitt godkjent innenfor EU/EØS for desinfeksjonsformål. Uoverensstemmelsen dreier seg derfor ikke om produktets kvaliteter, men hvorvidt det kan selges som hånddesinfeksjon i det norske markedet frem til endelig formell godkjenning. Denne saken har heller ingen påvirkning på øvrige forsknings og utviklingsprosjekter i selskapet.

Mer om sakens bakgrunn:
I børsmelding sendt 28.1.2022 opplyste Selskapet om Miljødirektoratets brev om at tidligere tolkning av biocidreglementet opprettholdes med den følge at gjeldende overgangsbestemmelser ikke kan anvendes på Selskapets  hånddesinfeksjonsmidler. Selskapet har informert fortløpende gjennom høsten 2021 om prosessen med å få avklart anvendelsesområdet for overgangsordningen, herunder at Miljødirektoratet avslo Selskapets anmodning om overgangsordning for sine hånddesinfeksjonsprodukter. Miljødirektoratets begrunnelse er basert på at biocidregelverket og overgangsordningen tolkes dithen at biocidprodukter med aktivt klor frigjort fra hypoklorsyre ikke er tillatt etter overgangsbestemmelsene uavhengig om det er til hånddesinfeksjon eller i kombinasjon med andre produkttyper. Biocidregelverket er et EU-regelverk og EU kommisjonen har tolket dette motsatt av Miljødirektoratet og har bekreftet at SoftOx sine hånd og overflate desinfeksjonsprodukter kan omsettes under gjeldende overgangsordning (jf. børsmelding 1. desember 2021).

Det faktum at Miljødirektoratet, til tross for EU kommisjonens uttalelse, velger å holde fast på sin tidligere tolkning av EUs biocidregelverk, gjør situasjonen utfordrende for SoftOx. Selskapet hadde, og har, en forventning om at Miljødirektoratet vil legge til grunn samme tolkning av EU regelverket som EU kommisjonen. Selskapet har derfor besluttet at det er behov for å forfølge saken for å få avklart anvendelsesområdet til gjeldende overgangsordning i Norge. Dersom Miljødirektoraret fastholder sitt standpunkt, vil Selskapet gå til rettslige skritt for å beskytte sine interesser og søke å få en avklaring av regelverket av domstolene.

Selskapets desinfeksjonsprodukter for overflater er i markedet ihht. overgangsordningen i Biocidforeskriften. Miljødirektoratets brev er en tolkningsuttalelse og SoftOx vil, inntil annet blir pålagt dem, forholde seg til EU kommisjonens tolkning av anvendelsesområdet for overgangsordningen og beholde sin hånd og overflatedesinfeksjon i markedet.

For mer informasjon, kontakt:
Geir Almås, administrerende direktør SoftOx Solutions AS
Mail: ir@soft-ox.com
Telefon sentralbord: (+47) 948 59 599

Om SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, notert på Euronext Growth Oslo) er et norsk
BioTech-selskap med base i Oslo med formål om å bidra til å bekjempe store
trusler mot menneskers helse, nemlig fremveksten av antimikrobiell resistens
(AMR), biofilminfeksjoner i kroniske sår og spredning av virus. For mer
informasjon om SoftOx, besøk www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx) har i dag mottatt brev fra Miljødirektoratet hvor det meddeler i brevet at det inntil videre opprettholder sin tidligere tolkning av det europeiske biocidreglementet, fremfor EU kommisjonens tolkning. Dette innebærer at Miljødirektoratet inntil videre legger til grunn at biocidprodukter med aktivt klor frigjort fra hypoklorsyre i Norge ikke er tillatt etter overgangsbestemmelsene uavhengig om det kun er til hånddesinfeksjon eller i kombinasjon med andre produkttyper (PT2). Denne tolkningen er det motsatte av hva EU kommisjonen konkluderte tidligere (som meddelt i børsmelding 1. desember 2021).

Ettersom biocidforordningen er en EU forordning, har SoftOx innrettet seg etter EUs fortolkning og er ikke enige i Miljødirektoratets tolkning. Miljødirektoratets holdning til saken er derfor svært overraskende for selskapet, og selskapet må vurdere hvilke skritt de ønsker å ta.

For mer informasjon, kontakt:
Geir Almås, administrerende direktør SoftOx Solutions AS
Mail: ir@soft-ox.com
Telefon sentralbord: (+47) 948 59 599

Informasjonen gitt i denne meldingen er definert som innsideinformasjon iht. MAR artikkel 7, og offentliggjøres i samsvar med MAR artikkel 7. Kunngjøringen er gjort av kontaktperson.

Om SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, notert på Euronext Growth Oslo) er et norsk
BioTech-selskap med base i Oslo med formål om å bidra til å bekjempe store
trusler mot menneskers helse, nemlig fremveksten av antimikrobiell resistens
(AMR), biofilminfeksjoner i kroniske sår og spredning av virus. For mer
informasjon om SoftOx, besøk www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

With reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on 2 July 2021, SoftOx has chosen to temporarily withdraw the
application. The biocidal products covered by the transitional arrangement will not be affected, and a new application will be submitted by the deadline of 1
July 2022. The transitional arrangement ensures the company’s presence in the market. The reason why the company chooses to withdraw the application is a
desire to rework and optimize the new application so that it better suits the changed conditions that now apply.

When the application was first prepared, it was based on the Norwegian Environment Agency’s recommendations and guidelines, which have subsequently proved to be unclear and not applicable, as well as the later lack of coincidence between the Norwegian Environment Agency and the EU Commission’s interpretations in significant areas.

A new application will be submitted in accordance with the EU Biocidal Regulations by 1 July 2022. The transitional arrangement is therefore valid if a new application is submitted by this date.

Furthermore, SoftOx states that the products for surface disinfection have received approval from the Norwegian Medicines Agency for use in the health care system.

The company has started to deliver to Hospital Purchasing (HINAS) and other players both within and outside the health sector.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx) are pleased to announce that the uptake of patients into the SBE-01 clinical study has improved considerably the past weeks, leading to completion of the first two dose-level cohorts.

Due to lack of Serious Adverse Events / Adverse Events, the Safety Monitoring Committee were unanimous on escalation to the next dose-level. Although early in the study, we see that our solutions are well tolerated in chronic wounds and confirm so far what was documented in previous animal models, says Glenn Gundersen, Chief Medical Officer in SoftOx Solutions.

SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the SoftOx’ lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, CMO SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Reference is made to the stock exchange announcement by SoftOx Solutions AS (the “Company”) published on 15 December 2021 regarding the successfully completed private placement of approximately NOK 50 million through the issue of new shares in the Company at a subscription price of NOK 55 per share (the “Private Placement”). In the announcement it was expressed that the Company would consider undertaking a subsequent offering of up to 218,000 new shares at the same subscription price as in the Private Placement, depending on the development of the price of the shares in the Company after completion of the Private Placement.

The board of directors has resolved not to proceed with the Subsequent Offering. Following announcement of the Private Placement, the Company’s shares have traded around or below the subscription price in the Private Placement. Accordingly, any shareholder wishing to reduce the dilutive effect of the
Private Placement have had the opportunity to purchase shares in the Company in the market at prices similar to or below what would have been the subscription price in the Subsequent Offering.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 29 December 2021 regarding the Company’s extraordinary general meeting resolving to issue 259,403 new shares in the Company against a set-off of NOK 9,999,985.65 of Almhaug Bolig AS’ claim against the Company under a loan agreement dated 13 October 2021.

The share capital increase pertaining to the debt conversion of NOK 5,188.06 divided on 259,403 shares has today been registered in the Norwegian Register of
Business Enterprises (Nw: Foretaksregisteret).

Following the share capital increase, the new share capital in the Company is NOK 206,857.42 divided into 10,342,871 shares, each with a nominal value of NOK 0.02.

The new shares will be listed and tradable on Euronext Growth Oslo from issuance in the Central Securities Depository (VPS).

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

An extraordinary general meeting of SoftOx Solutions AS (the “Company”) was held today on 29 December 2021 at 10.00. The general meeting was held as a video conference meeting. 2 225 622 shares were represented, corresponding to 24 % of the Company’s total share capital.

The general meeting approved all the proposals on the agenda in line with the notice dated 17 December 2021.

Signed minutes from the general meeting are attached to this announcement and will be made available on the Company’s website.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

  550492_SoftOx Solutions – EGM minutes (Engelsk) – signert.pdf
  550492_SoftOx Solutions – EGM minutes (Norsk) – signert.pdf
  550492_Vedlegg 1 Liste over representerte aksjonærer og stemmeresultater.pdf
  550492_Vedlegg 2 Vedtekter.pdf

Oslo, Norway, December 28, 2021: Harefrøken Invest AS, a legal person closely associated with a person discharging managerial responsibilities in SoftOx
Solutions AS, CEO Geir H. Almås, has notified the company of sale of shares in SoftOx Solutions AS, to J G Invest AS, where Kristian Almås is chairman of the
board.

Please refer to the attached for further information.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftfOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

  550460_Notification of transactions (KRT-1500).pdf

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 15 December 2021 regarding the successfully completed private placement of 915,000 new shares.

The share capital increase pertaining to the private placement of NOK 18,300 divided on 915,000 shares has today been registered in the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

Following the share capital increase, the new share capital in the Company is NOK 201,669.36 divided into 10,083,468 shares, each with a nominal value of NOK 0.02.

The new shares will be listed and tradable on Euronext Growth Oslo from issuance in the Central Securities Depository (VPS).

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Notice is hereby given of an extraordinary general meeting of SoftOx Solutions AS (the “Company”) to be held on the 29 December 2021 at 10:00.

Pursuant to section 5-8 of the Norwegian Private Limited Liability Companies Act and due to the ongoing COVID-19 pandemic, the extraordinary general meeting will be held as a video conference meeting without physical attendance for the shareholders. Shareholders who wish to participate electronically must send a notice of attendance to the Company by 28 December 2021 at 12:00 in accordance with the attached notice of attendance form. Details for the video conference meeting will only be provided to shareholders who have given notice in advance.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Mundal Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses.

For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

  549806_SOftOx Solutions – EGM notice with appendices.pdf

Issuer name: SoftOx Solutions AS
Ex. Date: 16 December 2021
Type of corporate action: potential repair offering

This information is published in accordance with the requirements of the Euronext Growth Oslo RB II – Issuer Rules

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SotfOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

More information:
Access the news on Oslo Bors NewsWeb site

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) published on 15 December 2021 regarding a completed private placement of 915,000 new shares raising gross proceeds of NOK 50 million (the “Private Placement”), where it was announced that the Company will consider conducting a subsequent repair offering of up to 218,000 new shares (the “Repair Offering”) with non-tradeable subscription rights, which, subject to applicable securities laws, will be directed towards existing shareholders in the Company as of 15 December 2021 (as registered in the VPS two trading days thereafter), who (i) were not allocated shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful or (ii) in other jurisdictions than Norway, would require a prospectus, filing, registration or similar action. The Company may allow for subscriptions without subscription rights.

Key information:
Date on which the terms of the Repair Offering was announced: 15 December 2021
Last day including right to receive subscription rights: 15 December 2021
First day excluding right to receive subscription rights (ex-date): 16 December 2021

Record date: 17 December 2021
Maximum number of new shares: 218,000
Subscription price: NOK 55 per share
Maximum gross proceeds: Approx. NOK 12 million
Will the subscription rights be listed: No

The Repair Offering is, inter alia, conditional upon the extraordinary general meeting resolving to grant the board of directors an authorisation to increase the share capital, the board of directors resolving to initiate the Repair Offering, and the publication of a prospectus in accordance with applicable
legislation. Whether or not the Repair Offering will take place will depend on inter alia the development of the trading price of the Company’s shares.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Important information

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “EU Prospectus Regulation” means Regulation (EU) 2017/1129 as amended (together with any applicable implementing measures in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (A) (i) persons who have professional experience, knowledge and expertise in matters relating to investments and are “investment professionals” for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities and other persons falling within Article 49(2)(a) to (d) of the Order and (iii) persons to whom it may otherwise lawfully be communicated; and (B) persons who are “qualified investors” within the meaning of the EU Prospectus Regulation as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (all such persons being referred to as “relevant persons”). Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict, and are beyond their control. Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in public sector investment levels, changes in the general economic, political and market conditions in the markets in which the Company operates, the Company’s ability to attract, retain and motivate qualified personnel, changes in the Company’s ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

More information:
Access the news on Oslo Bors NewsWeb site

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) published on 15 December 2021 regarding a contemplated private placement of new shares in the Company (the “Private Placement”).

The Company is pleased to announce today that it has raised approx. NOK 50 million in gross proceeds through the Private Placement by issuance of 915,000
new shares in the Company (the “New Shares”), at a price per New Share of NOK 55 (the “Subscription Price”). The Private Placement took place through an
accelerated bookbuilding process managed by SpareBank 1 Markets AS (the “Manager”) after close of markets on 15 December 2021. The Private Placement was oversubscribed.

The net proceeds from the Private Placement will be used to fund commercial activities related to bringing the Hand Disinfection and Wound Irrigation
Solution to the European and the US market as well as finalization of phase 1 development of the Infection Remover (BE) and for general corporate purposes.

Allocation to investors and payment instructions are expected to be communicated on or about 16 December, and the settlement in the Private Placement is expected to be on or about 20 December 2021 (DVP). Settlement of the New Shares will be made by delivery of existing and unencumbered shares in the Company that are already listed on Euronext Growth Oslo to be lent from Dinge Invest AS (the “Share Lender”) by the Manager pursuant to a share lending agreement between the Manager, the Company and the Share Lender (the “Share Loan”). Accordingly, the shares delivered to the investors will be tradable from allocation.

The Share Loan will be settled by the Manager with new shares in the Company, which has been resolved by the board of directors of the Company (the “Board”) pursuant to an authorization granted by the Company’s annual general meeting on 13 April 2021.

Following registration of the share capital increase pertaining to the Private Placement with the Norwegian Register of Business Enterprises, the Company will
have a share capital of NOK 201,669.36, divided into 10,083,468 shares, each with a par value of NOK 0.02.

In relation to the Private Placement, Almhaug Bolig AS has exercised its right to convert NOK 10 million of its short-term unsecured interest-free loan, with a
principal amount of NOK 15 million, into new shares in the Company at a conversion price of NOK 38.55 per share in accordance with the loan agreement
between the Company and Almhaug Bolig AS dated 13 October 2021 (the “Debt Conversion”). The subscription price per share was agreed in the loan agreement based on the volume weighted average share price in the days prior to the loan was granted on 13 October 2021. The Debt Conversion is subject to completion of the Private Placement and resolution by the Company’s extraordinary general meeting to issue the new shares in a share capital increase by way of conversion of debt, scheduled to be held on or about 29 December 2021 (the “EGM”).

Subject to satisfaction of the conditions for completion of the Private Placement, the Board has resolved to propose that the EGM resolves to authorize the Board to carry out a subsequent offering of up to 218,000 new shares (the “Subsequent Offering”) towards the Company’s shareholders as of 15 December 2021 (as documented by the shareholder register in the Norwegian Central Securities Depository (VPS) as of 17 December 2021, the “Record Date”) who were not allocated shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful or, for jurisdictions other
than Norway, would require any prospectus, filing, registration or similar action (“Eligible Shareholders”).

The subscription price in the Subsequent Offering will be the same as the Subscription Price in the Private Placement, i.e. NOK 55 per share. The Subsequent Offering will be conditional, inter alia, on (a) completion of the Private Placement, (b) approval of the authorization of the Board for the Subsequent Offering by the Company’s shareholders at the EGM, and (c) publication of an offer prospectus by the Company. Whether the Subsequent Offering will ultimately be completed, will also depend on the development of the price of the shares in the Company after completion of the Private Placement and the Debt Conversion. The Company will issue a separate stock exchange notice with further details on the Subsequent Offering when finally resolved.

Advokatfirmaet Wiersholm AS is acting as legal advisor to the Company in connection with the Private Placement.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information pursuant to MAR article 7, and is publicly disclosed in accordance with MAR article 17. The announcement is made by the contact person.

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Important information

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “EU Prospectus Regulation” means Regulation (EU) 2017/1129 as amended (together with any applicable implementing measures in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (A) (i) persons who have professional experience, knowledge and expertise in matters relating to investments and are “investment professionals” for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities and other persons falling within Article 49(2)(a) to (d) of the Order and (iii) persons to whom it may otherwise lawfully be communicated; and (B) persons who are “qualified investors” within the meaning of the EU Prospectus Regulation as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (all such persons being referred to as “relevant persons”). Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict, and are beyond their control. Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in public sector investment levels, changes in the general economic, political and market conditions in the markets in which the Company operates, the Company’s ability to attract, retain and motivate qualified personnel, changes in the Company’s ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

More information:
Access the news on Oslo Bors NewsWeb site

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

SoftOx Solutions AS (the “Company”) has engaged SpareBank 1 Markets AS (the “Manager”), to advise on and effect a contemplated private placement of up to 915,000 new shares (the “New Shares”) in the Company (the “Private Placement”).

The net proceeds from the Private Placement will be used to fund commercial activities related to bringing the Hand Disinfection and Wound Irrigation Solution to the European and the US market as well as finalization of phase 1 development of the Infection Remover (BE) and general corporate purposes.

The final subscription price per New Share (the “Subscription Price”) and the final number of New Shares to be issued, and as such, the total gross proceeds from the Private Placement, will be determined through an accelerated book building process. The Private Placement will be directed towards a limited number of selected investors, in each case, subject to and in compliance with applicable exemptions from relevant prospectus, filing and registration requirements. The minimum application and allocation amount have been set to the NOK equivalent of EUR 100,000. The Company may however, at its sole discretion, allocate an amount below the NOK equivalent of EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations, including Regulation (EU) 2017/1129 and ancillary regulations, are available.

The bookbuilding period for the Private Placement starts on 15 December at 16:30 hours (CET) and closes on 16 December 2021 at 08:00 hours (CET) (the “Application Period”). The Company, together with the Manager, reserves the right, at its own discretion, to extend or shorten the Application Period or modify the terms of or cancel the Private Placement at any time (prior to completion) and for any reason and on short notice. The allocation of New Shares will be determined following the expiry of the Application Period and the final allocation will be made by the board of directors of the Company. Notification of allocation and payment instructions is expected to be issued to the applicants on or about 16 December 2021 through an allocation letter to be issued by the Manager (the “Notification”).

The allocated New Shares in the Private Placement will be delivered to the applicant’s VPS account on a delivery versus payment (DVP) basis. Settlement for the New Shares is expected to be on or about 20 December 2021. The New Shares will be settled by delivery of existing and unencumbered shares in the Company that are already traded on Euronext Growth Oslo to be lent from Dinge Invest AS (the “Share Lender”) by the Manager pursuant to a share lending agreement between the Manager, the Company and the Share Lender (the “Share Loan”). The allocated New Shares will be delivered to the applicant’s VPS account as soon as practicable after full payment has been received and the Conditions (as defined below) for the Private Placement have been met. The Manager will settle the Share Loan with new shares in the Company to be resolved issued by the board of directors pursuant to the Board Authorization (as defined below).

Completion of the Private Placement is subject to the following conditions (the “Conditions”): (i) the board resolving to consummate the Private Placement, allocate the New Shares and issue the New Shares pursuant to the authorization to increase the share capital of the Company granted by the Company’s annual general meeting of 13 April 2021 (the “Board Authorization”), (ii) the share capital increase pertaining to the issuance of the allocated New Shares being validly registered with the Norwegian Register of Business Enterprises and the allocated New Shares being validly issued and registered in the VPS, and (iii) the Share Lending Agreement not being terminated prior to allocation.

Almhaug Bolig AS has, in connection with the Private Placement, exercised its right to convert NOK 10 million of its short-term unsecured interest-free NOK 15 million loan to the Company, into new shares in the Company at a conversion price of NOK 38.55 per share in accordance with the loan agreement between the Company and Almhaug Bolig AS dated 13 October 2021 (the “Debt Conversion”). The subscription price per share was set based on the volume weighted average share price in the period before the loan was granted. The Debt Conversion is subject to completion of the Private Placement and the resolution by the Company’s extraordinary general meeting to issue the new shares in a share capital increase by way of conversion of debt, which is expected to be held on or about 29 December 2021.

The Private Placement represents a deviation from the shareholders’ pre-emptive right to subscribe for the New Shares. The board of directors has considered the Private Placement in light of the equal treatment obligations under the Norwegian Securities Trading Act and the rules of equal treatment set out in the continuing obligations for companies admitted to trading on Euronext Growth and Oslo Børs’ guidelines on the rules of equal treatment, and has concluded that there is a basis for deviating from the existing shareholders’ preferential rights. The board of directors has in this respect, inter alia, taken into consideration (i) that the Company needs funding to pursue its growth strategy and that the Private Placement allows the Company to utilize the current trading prices of the shares and favourable market conditions, in particular in light of the volatility in the Company’s shares; (ii) that the Private Placement gives the ability to broaden and strengthen the Company’s shareholder base; (iii) the size of the Private Placement; and (iv) the availability of the shares in the open market. The board of directors has concluded that the Private Placement is in compliance with these requirements.

The Company may, subject to completion of the Private Placement and the EGM approving an authorization to the Board or an issuance of shares to this effect at the EGM, and certain other conditions, consider a subsequent repair offering of new shares (the “Subsequent Offering”) at the final Subscription Price and otherwise in line with market practice. Shareholders being allocated shares in the Private Placement will not be eligible to participate in a Subsequent Offering. The Company reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering.

Advokatfirmaet Wiersholm AS is acting as legal advisor to the Company in connection with the Private Placement.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Important information
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to “qualified institutional buyers” as defined in Rule 144A under the Securities Act. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “EU Prospectus Regulation” means Regulation (EU) 2017/1129 as amended (together with any applicable implementing measures in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (A) (i) persons who have professional experience, knowledge and expertise in matters relating to investments and are “investment professionals” for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities and other persons falling within Article 49(2)(a) to (d) of the Order and (iii) persons to whom it may otherwise lawfully be communicated; and (B) persons who are “qualified investors” within the meaning of the EU Prospectus Regulation as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (all such persons being referred to as “relevant persons”). Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict, and are beyond their control. Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in public sector investment levels, changes in the general economic, political and market conditions in the markets in which the Company operates, the Company’s ability to attract, retain and motivate qualified personnel, changes in the Company’s ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement. The distribution of this announcement and other information may be restricted by law
in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

More information:
Access the news on Oslo Bors NewsWeb site

The Swedish Purchasing organization has, on behalf of the regions of Uppsala, Dalarna, Västmanland, Örebro and Sörmland, carried out a tender for
Chemical-technical products, and announces today that SoftOx Solutions AS (SoftOx) has won the tender in both categories in which they participated, which is ”Surface disinfection with sporicidal effect” and ”Hypochlorite-based surface treatment with sporicidal effect”.

”This is a milestone for SoftOx and the first time we win a tender outside of Norway. This confirms that our unique products are of very high quality. This in
addition to winning the category for non-alcoholic hand disinfection for all hospitals in Norway, provides a very good foundation for our future investments
internationally”, says CEO Geir Almås of SoftOx Solutions.

Recently, SoftOx announced that the EU Commission’s interpretation of the Biocides Regulations is in line with SoftOx’s view, which means that SoftOx can
enter the market with all its disinfection products in the EU and the EEA area.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx) has previously been refused on a request for a transitional arrangement from the Norwegian Environment Agency for its hand
disinfection products. In this context, the company has requested an assessment and a clarifying statement from the European Commission.

Will be able to deliver on the National Hospital Tender (HINAS) and European markets
The company’s interpretation of the Biocidal Regulations is in line with the Commission’s statement regarding the possible transitional arrangements for the
company’s hand and surface disinfectants.

“This is very good news for SoftOx. In our opinion the European Commission’s assessment will enable us to make our products available on the market and we will be able to fulfil our obligations in accordance with the HINAS agreement. The European Commission’s analysis and assessment means that SoftOx can, if the company wants to, go to all European markets with its disinfectant products for hand and surface”, says CEO Geir Almås.

“We are ready to meet increased demand”
The company have a pending application in process in the Norwegian Environment Agency for approval of the company’s hand and surface disinfection products. The transitional arrangement described by the EU Commission gives the company the opportunity to have the hand and surface products on the market until final approval of the pending application is available.

“This is a scenario we have prepared for by buying 50 percent of Ose Water. We are ready to meet potential increased demand from major European markets”,
according to Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

The Research Council has allocated approximately 2.4 MNOK to SoftOx Solutions AS’s subsidiary SoftOx Defense Solutions (SDS) for the completion of a PhD for the development of a multi-product for the Armed Forces. The PhD program is a 3rd year program in collaboration with the Norwegian Defense Research Establishment (FFI) and the Department of Pharmacy at the University of Oslo. The companies will research and develop a multi-product for disinfection and wound wash, increasing the operational capability of Norwegian soldiers.

– The grant is highly appreciated and it is important for further development of the project “multiproduct” that The Research Council provides this award, says
CEO of SoftOx Defense Solutions, Rune Jomaas. The PhD candidate is already active working both at the Norwegian Defense Research Establishment and the
Department of Pharmacy.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CEO Rune Jomaas of SoftOx Defense Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS works in a pan-European consortium to develop military countermeasures against chemical substances, biological agents, radioactive substances and nuclear material, so-called CBRN substances, for use in the Norwegian Armed Forces and the EU’s military forces.

In April 2021, SoftOx entered a three-year research collaboration with the Norwegian Defence Research Establishment (FFI) to improve the operational capability of Norwegian and international soldiers. In this connection, the subsidiary SoftOx Defense Solutions AS (SDS) was established. Based on SoftOx technology, SDS develops military applications for the Norwegian Armed Forces, the EU’s military forces, NATO and the US Armed Forces. The work with the consortium lies in this company.

The consortium is led by France and the application is sent to the European Defense Fund (EDF) on 9 December 2021. The research work is based on SoftOx’s technology as a basis for the development of military countermeasures and has a total estimated total of approx. NOK 500 million (Euro 50 million). SDS’s share is estimated at approximately NOK 120 million (Euro 12 million) to develop a military inhalation solution for the EU. The company will apply to EDF to cover 80 percent of the costs associated with the project, ie NOK approx. 96 million (Euro 9.6 million). The Norwegian contribution must account for the rest, ie approx. NOK 24 million (Euro 2.4 million)

The Ministry of Defense has decided to guarantee 40 percent of the Norwegian contribution through so-called co-financing and has allocated SDS a total of 10.6 MNOK to the project.

– This is a sign of quality and a declaration of confidence from the Ministry of Defence. We have big plans for SDS in the future, says CEO Geir Almås of SoftOx Solutions.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

SoftOx Solutions AS is pleased to invite investors, analysts and other stakeholders to our Strategy and Capital Markets Day, including Q3 2021 results on Wednesday the 17^th of November 2021 at 09.00 to 12.00 (CET).

Schedule:

09.00-09.10     Opening with CEO Geir Almås

09.10-10.00     Technology platform and business strategy

10.00-11.30     Program areas for development

11.30-11.45     Finance

11.45-12.00     Q&A

The event will be held in-person at Technopolis, Martin Linges Vei 25, 1364 Fornebu, Norway. It will also be streamed live.

Please register for the event, before 15^th of November 2021, by sending an email to ir@soft-ox.com

The Q3 2021 results will be released at 07:00 (CET) on Wednesday November 17, 2021. The interim report and related materials will be made available on: https://soft-ox.com/financial-calendar-reports/.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Mundal Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

(SoftOx) We are pleased to announce that the first patient has been recruited to the SBE-01 clinical study. After having experienced unforeseen challenges regarding access to and availability of eligible patients, mainly due to the nationwide nurse strike in Denmark, it is reassuring that the study team has now been able to screen and select several patients for the study, says Glenn Gundersen, Chief Medical Officer in SoftOx Solutions.

SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the SoftOx’ lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, Glenn Gundersen
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx) have announced today that the first subject has received SoftOx Inhaled Solution (SIS), in the first-in-human Phase 1 trial. SIS is an aerosolized pan-antimicrobial product intended for the treatment of upper and lower respiratory tract viral and bacterial infections. The trial is part of a development program for the use of SIS in the treatment of SARS-CoV-2 (COVID-19) and other respiratory tract infections, and is a collaboration between SoftOx and University of Copenhagen.

The first subject received a single administration of low dose SIS. Healthy volunteers will receive three escalating doses of SIS or placebo, nebulised as a single dose once, twice or four times daily for 5 days.

SIS is a stabilised solution of hypochlorous acid that can be aerosolised and inhaled. The antimicrobial properties of hypochlorous acid are well described, and endogenous production of hypochlorous acid is one of the key elements involved in host immunity from infectious disease.

“The SoftOx technology platform is a stabilised formulation of hypochlorous acid that permits aerosolization using a jet nebulizer” says Dr Christopher Burton, Chief Medical Officer for SIS. “The SIS-01 trial will evaluate safety and tolerability of three different concentrations administered up to four times daily, which will provide the basis for future studies evaluating efficacy in COVID-19 and other respiratory tract infections.”

SIS-01 (EudraCT No.: 2020-004462-19) is a single-centre, randomised, double-blind, placebo-controlled, study will explore the safety and tolerability of single and multiples doses of inhaled nebulised SIS in healthy subjects.

“This is another important milestone in the development of a pharmaceutical product for which there is a huge unmet need,” says Geir Almås, CEO.

“Society faces a growing threat of new emergent viral strains and increasing antimicrobial resistance to currently available treatments. SIS has the potential to fill that need.”

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, SIS, Christopher Burton
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

The board of SoftOx Solutions AS has entered into a loan agreement with Almhaug Bolig AS, where the main shareholder is one of the shareholders. Almhaug Bolig AS will provide the company with a short-term loan of NOK 15 million.

“In the last year, the company has experienced some delays both in connection with regulatory processes with the authorities and in the implementation of certain clinical studies. To compensate for the liquidity burden caused by these delays, the company’s main shareholder has given the company a loan of NOK 15 million. Additional supply of liquidity may be considered if desired. The company is grateful that the company’s main shareholder shows his support for the company I this situation. It is important for the company to have owners who are dynamic and support the company financially in such situations”, says CEO Geir Almaas of SoftOx Solutions.

“We work with several exciting processes. Among other things, we recently received approval from the Danish Medicines Agency to start SIS (SoftOx Inhalation solution) studies in humans. For us, this is a very exciting race, which we have high expectations for”, Almås continues.

The loan has a maturity of 12 months and is not interest-bearing. The loan will in principle be repaid in cash, but until the maturity of the loan, Almhaug Bolig AS will have the right to convert the loan into equity in the company by issuing new shares at a price equal to the volume- weighted average share price in the last five days before entering into the agreement, minus five percent, NOK 38,551 per share. The board is of the opinion that the discount is commercially justified as the loan is interest-free. If the company carries out a share issue before the loan matures or is converted into shares, Almhaug Bolig AS will have the right to convert the loan into shares at the same price per share as the subscription price in such an issue.

New shares that may be issued in connection with the conversion right will be approved by the company’s board in accordance with the authorization given by the annual general meeting on 13 April 2021. The board has assessed the loan agreement and the right of conversion in relation to the rules on equal treatment and is of the opinion that there is a valid reason for differential treatment.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

OSLO – October 6, 2021: SoftOx Solutions AS (SoftOx) have announced today that the Danish Medicines Agency (DKMA) approved the Phase 1 clinical trials for SoftOx Inhaled Solution (SIS), an aerosolized antimicrobial product intended for the treatment of upper respiratory tract infections (e.g., influenza and common colds) and lower respiratory tract infections (e.g., pneumonia and bronchitis).

“SIS would be a game changer in the treatment of viral and bacterial infections in the respiratory tract”, says CEO Geir Almås at SoftOx Solutions.

“Soon commencing human trials”

The Phase 1 trial is part of a development program for the use of SIS in the treatment of respiratory tract infections starting with SARS-CoV-2 (COVID-19) infections. This trial is scheduled to commence in autumn 2021, in Denmark.

“We are pleased to have satisfied the Danish Medicines Agency requirements, and that we will soon commence this first-in-human trial of SoftOx Inhaled Solution”, says Dr Christopher Burton, Chief Medical Officer for SIS.

SIS is a stabilised solution of hypochlorous acid that can be aerosolised and inhaled. The antimicrobial properties of hypochlorous acid are well described, and endogenous production of hypochlorous acid is one of the key elements involved in host immunity from infectious disease.

“Hypochlorous acid is extremely effective in killing viruses and bacteria in vitro. Up until now, the problem has been maintaining hypochlorous acid in a stable form until delivery to the target tissues,” says Dr Burton.

First major step
SIS-01 (EudraCT No.: 2020-004462-19) is a single-centre, randomised, double-blind, placebo-controlled study, the study will explore the safety and tolerability of single and multiples doses of inhaled nebulised SIS in healthy subjects.

“This is the first major step in the development of a pharmaceutical for treatment of the respiratory tract based on SoftOx Solutions proprietary technology for the stabilisation of hypochlorous acid,” says Almås.

“SIS would be a game changer in the treatment of viral and bacterial infections in the respiratory tract. SIS is particularly relevant in the context of the current pandemic and for future epidemics and pandemics, and the emerging threat of antimicrobial drug resistance”, continues Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, SIS, Christopher Burton
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Update regarding the ongoing application process for national approval of biocidal products (disinfection products) in Norway (with reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on March 29 and September 17, 2021).

The Ministry of Climate and the Environment has not upheld the postponed implementation of whether there should be a deadline in Norway for SoftOx to suspend sales by 3 October 2021, for SoftOx disinfection based on active chlorine released from sodium hypochlorite.

-We do not understand this decision. It is important to emphasize that this has nothing to do with the quality of and clinical documentation of the product, says CEO Geir Almås in SoftOx.

The notice concerns the application for disinfection based on active chlorine released from sodium hypochlorite, where there has been an ongoing appeal process in the Ministry of Climate and Environment regarding the approval of SoftOx disinfection. This application was rejected by KemI in Sweden, and has been appealed to the Land and Environmental Courts in Sweden. Pending a decision from Sweden, SoftOx has applied to the Ministry of Climate and Environment in Norway to remain in the market with the product in question. The current deadline for SoftOx to suspend sales is by October 3, 2021, with the possibility of continued use for a period of six months thereafter. SoftOx has now received a rejection of the request for deferred implementation of decisions. It is pointed out, however, that when SoftOx is upheld in Sweden, the product will be able to be put back on the market in Norway.

The Ministry justifies its refusal on the grounds that: “It is therefore only a question of a temporary loss of revenue” and further writes: “The consequences of the decision are reversible, in the sense that the product can be relaunched on the market.”

– The Ministry has based their decision on process and unfortunately shows little understanding of the importance of keeping the product in the market. The positive is that the Ministry states that the processing of our application will be prioritized, says Almås

SoftOx is now taking a thorough review of the letter from the Ministry of Climate and the Environment and continues the active dialogue with both KemI in Sweden.

– We perceive the dialogue with KemI as very constructive and good, and are optimistic about a positive outcome, says Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

Update regarding the ongoing application process for national approval of biocidal products (disinfection products) in Norway (with reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on March 29th and July 2. 2021).

The Norwegian Environment Agency has rejected that SoftOx ‘hand disinfection can be covered by a transitional scheme during the period in which the application for product approval is processed. The Norwegian Environment Agency’s interpretation of the regulations is disputed by SoftOx.

– The company does not understand the directorate’s interpretation of the text in the hearing proposal. The situation has been assessed together with leading lawyers. Our opinion is that the NEA here has made a mistake. That SoftOx as a small company should now bear the risk of mistakes made by the Norwegian Environment Agency is perceived as grossly unfair, says CEO Geir Almås of SoftOx Solutions.

SoftOx has two processes towards regulatory authorities associated with its disinfection products: application for approval based on active chlorine released from hypochloric acid and an application for approval based on active chlorine released from sodium hypochlorite. The products are identical, except for a regulatory term for active substance. The fact that the company has two ongoing application processes is because the regulations are complex and that they are interpreted differently from country to country.

SoftOx’s application for approval of the product family in disinfection based on active chlorine released from hypochlorous acid has been submitted in accordance with requirements specified in the Norwegian Environment Agency’s hearing memorandum from March 2021 to new regulations (2021/2157). SoftOx bases its opinion on the fact that there is a transitional arrangement for all disinfection products when the application for approval was submitted within the deadline specified in the hearing memorandum. However, the Norwegian Environment Agency has by letter, and as part of an ongoing dialogue, announced that the that there should be no transitional scheme for products based on active chlorine from hypochlorous acid Product type 1 (hand disinfection).

Without a valid transitional arrangement or temporary permit, SoftOx cannot place its disinfectant products based on this active substance on the market until the Norwegian Environment Agency has approved SoftOx’s new application. SoftOx is now undertaking a thorough review of the letter from the Norwegian Environment Agency and is considering submitting the case to the Ministry of Climate and Environment.

In addition to the application for disinfection based on active chlorine released from hypochlorous acid, there is an ongoing appeal process in the Ministry of Climate and Environment regarding the approval of SoftOx disinfection based on active chlorine released from sodium hypochlorite. This application was rejected by KemI in Sweden, and an appeal is pending in the Ministry of Climate and Environment as to whether there should be a deadline in Norway for SoftOx to suspend sales by October 3, 2021 with the possibility of continued use for a period of six months thereafter.

– We strongly disagree with the Norwegian Environment Agency’s perception of the regulations. We recently won the contract announced by HINAS (Helseforetakenes Innkjøpsservice AS) for hand disinfection products, which shows that our product is best in class. However, we believe in a good and fair treatment from the Ministry of Climate and Environment, to continue to deliver products to our customers. The conclusion is that the regulatory situation is still unclear, says CEO Geir Almås of SoftOx Solutions.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

SoftOx Solutions AS (SoftOx) has entered into an agreement to purchase 50 percent of the shares in Ose Water AS (Ose). According to the agreement, SoftOx will also move all production of disinfection products to Ose and thereby secure reliable production and delivery both nationally and internationally. The agreement ensures production volume at a competitive price with high quality in the years to come.

“This is an important strategic collaboration for us and forms the basis for growth and competitive production in the years to come. Partnering with a competent environment within production and bottling further professionalizes the company,” says CEO Geir Almås of SoftOx.

SoftOx experiences increased demand for the company’s disinfection products, which increases the need for safe and high-quality production.

“Having Ose on the team enables us to comply with the expected demand from Norwegian hospitals, and at the same time the expected increased demand both nationally and also internationally. In addition to the award in a national tender, the company has entered into agreements with a large Norwegian financial group and a Norwegian airline. We hope this is just the beginning, as we now expect other Norwegian customers to demand this product as well as major players are choosing our solution,” says Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

About Ose Water AS
Ose Water AS is a Norwegian natural mineral water producer located in Bygland.
Ose Water is bottled directly from the pure and natural mineral water source
Osekilden at Ose in Setesdal. The factory has a large capacity and several
production lines optimized for different products. For more information about
Ose Water, please visit www.osewater.com

More information:
Access the news on Oslo Bors NewsWeb site

Sykehusinnkjøp HF’s national tender – hygiene products, disinfectants and dispensing solutions for hand disinfectants, soap and cream (HINAS).

SoftOx Solutions AS (SoftOx) has participated in the HINAS tender mentioned here and reports that the company’s hand disinfectant product SafeDes® has been selected and will be listed in Norwegian hospitals as the only alternative to alcohol-based products following the decision in the national tender.

From the evaluation for subcontract 16, hand disinfectants without alcohol (bottles), SoftOx received a top score on the evaluation criteria “properties on
skin” and quality. The product is an alternative for those who have skin problems related to the use of alcohol. The skin does not feel sticky or dry
after use.

This, in combination with a competitive price, is the overall evaluation that SoftOx comes out best in the assessment.

The product has been assessed by the country’s foremost professional expertise on efficacy and safety in disinfection. This is a confirmation of our base
technology, and the decision clearly shows that the product has a place in the health care system. “Winning a national hospital tender is also a very important
reference for the company in other markets, in addition to being a confirmation of our research and our work so far. This award shows that our commitment to
health has been right and provides a good basis for further investment,” says CEO Geir Almås.

The company announces increased investment in its disinfection products. Based on the clear advantages of the products: skin friendliness, effect and security,
we will continue to invest in the categories defense, health, B2B and the transportation industry. We now see that the market responds within these
categories and are experiencing increased demand and sales. However, the Norwegian hospital market is the company’s pilot customer and is not expected to
provide profitability during the first years.

With reference to the stock exchange announcement on 2 July 2021, the company is still working on the basis that company will enter a transitional arrangement in the connection with the new biocidal regulations.

Further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

The first in human study of SoftOx Biofilm Eradicator started as planned at the end of May, but due to the ongoing nurses’ strike in Denmark, we do not expect
to be able to admit patients to the study until the strike is over. The strike is expected to last for approximately 10 weeks. The study is therefore expected
to be somewhat delayed; however, the company will strive to make up for lost time.

This is the phase I study with our lead wound care product, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE, to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine M. Rød, Financial Manager of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

With reference to the stock exchange announcement on March 29, 2021, SoftOx has now submitted a new application for national approval of its biocidal products in Norway. The application addresses the objections raised in the first application and only applies to the Norwegian market.

“The company experienced that the previous application involving Norway, Sweden and Denmark entailed great procedural complexity, which we consider to be a contributing factor to the application being rejected. The new improved application now addresses the weaknesses that were commented on in the previous application. New applications to other countries will be submitted on an ongoing basis. In addition, SoftOx has appealed the rejection of the first
application.” says CEO Geir Almås.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

More information:
Access the news on Oslo Bors NewsWeb site

23 JUN 2021 11:00 CEST

SoftOx Solutions AS (SoftOx) is pleased to announce that the results of the clinical investigation SoftOx Wound Irrigation Solution for acute wounds (SWIS) have been completed. The study, which has been conducted at Bispebjerg University Hospital in Copenhagen, is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (SWIS) compared to Normal Saline (NS) in a human wound model.

The study showed both significant improvement in wound healing and reduction in bacterial burden compared to Normal Saline (NS), positioning the product as superior towards today’s market leaders. Finishing the clinical development program strengthens the SoftOx platform for further product development. The results from the study “SWIS-02” confirm the excellent safety profile of the SoftOx technology platform, also strengthening the documentation of SoftOx hand disinfectant technology with regards to skin friendliness being superior to today’s alcohol-based hand disinfectant. The company now prepares to file their wound irrigation SWIS for final approval as a Medical Device in Europe.

SoftOx Wound Irrigation Solution (SWIS) will become a Medical Device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds. SWIS has the potential to become a favoured alternative to the current wound irrigation solutions on the market which have challenges related to safety (side effects, resistance development) and effect. According to market reports from The Insight Partners, the global market size for wound irrigation solutions was estimated at USD 1.6 billion in 2018, and yearly 190 million wounds is treated in hospitals. Finalization of the SWIS-02 study concludes the clinical evaluation part of the SWIS documentation package. SWIS is expected to be the company’s first CE-marked product for the European market.
Regarding the wound healing capabilities, the study meets its primary endpoint of re-epithelialization (non-inferior to NS) by day 10 with high significance (p<0.0001). Furthermore, early re-epithelialization at day 4 was significantly better than normal saline (mean 57% versus 43%, p<0.0001). Also, overall usability aspects of SWIS handling were reported to be satisfactory.

Once again SWIS demonstrates and confirms previous findings (from SWIS-01) to be safe and well tolerated as a wound irrigation solution for acute wounds and not associated with any major risks. Performance outcomes demonstrate antimicrobial properties with excellent wound healing (re-epithelialization) observations. “This has been a highly successful study with respect to implementation, conduct and outcome and clearly confirms the favourable properties of SWIS as an excellent wound irrigation solution,” says Glenn Gundersen, Medical Director of SoftOx.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

07 JUN 2021 07:00 CEST

SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for the treatment of respiratory tract infections. This has the potential to be a breakthrough in the future treatment of respiratory infections, including viruses, bacteria and fungal infections.

“After an intensive research phase, we are very satisfied that the Danish Medicines Agency (DKMA) considers our documentation positively and has given a conditional approval to be able to start the study”, says Medical Director Glenn Gundersen. “The conditions that have been communicated are related to additional safety data and the company is already working on completing the data as requested. The data will be provided in due time and we believe that the study can be initiated during the autumn.”

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

26 APR 2021 13:58 CEST

In connection with SoftOx Solutions AS reporting for the first quarter of 2021, SpareBank 1 Markets invites to a presentation with the company on Thursday 29 April at 1400.

Date: Thursday 29 April
Time: 14:00 – 15:00
RSVP: Registration to corporateaccess@sb1markets.no

More information:
Access the news on Oslo Bors NewsWeb site

13 APR 2021 19:46 CEST

Det ble avholdt en ordinær generalforsamling i SoftOx Solutions AS den 13. april 2021 kl. 09.00. På grunn av gjeldende restriksjoner mot innendørs arrangementer i Oslo kommune som følge av Covid-19, ble generalforsamlingen kun avholdet som elektronisk møte. 2 671 336 aksjer var representert, tilsvarende 29,14 % av selskapets totale aksjekapital.

Generalforsamlingen vedtok alle forslagene på agendaen i tråd med innkallingen datert 6. april 2021.

Signert protokoll fra generalforsamlingen er vedlagt denne meldingen og vil bli gjort tilgjengelig på selskapets hjemmeside.

More information:
Access the news on Oslo Bors NewsWeb site

09 APR 2021 08:00 CEST

The National Committee of Health Research Ethics (NVK) in Denmark has approved the “SBE-01 study”, a first-in-human, phase I clinical trial in patients with chronic wounds. The study has now received full regulatory clearance to make the
final preparations for initiation. Reference is made to the previous stock announcement of 15th March 2021 regarding authorisation from the Danish Medicines Agency.

“This rapid approval by the relevant regulatory bodies in Denmark will enable us to start the study during Q2-2021” says Glenn Gundersen, Medical Director in SoftOx Solutions.

SBE-01: EudraCT no. 2021-000314-42.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working
to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

06 APR 2021 09:00 CEST

SoftOx Solutions AS will be holding its Annual General Meeting [virtually] on 13 April 2021 at 09:00 hours (CET).

The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: https://soft-ox.com/.

All shareholders are encouraged to exercise their shareholder rights, either by using the enclosed proxy form to provide proxy to the Chairman Melvin Teigen (or the person he appoints), or to attend the general meeting virtually.

Shareholders who wish to participate electronically must register using the attached notice of attendance in order to receive a link to the general meeting. The notice of attendance and proxy form must be received prior to 12 April 2021 at 15:00. Notice of attendance and proxy form are attached to this notice.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

29 MAR 2021 14:32 CEST

With reference to the stock exchange announcement from SoftOx Solutions AS (“SoftOx”) on December 11th, 2020, when SoftOx received information from the Swedish Chemicals Agency that the application for SoftOx Disinfection Products was sufficiently complete to proceed to the final decision-making. Contrary to
this statement, the Swedish Chemicals Agency changed its initial position by rejecting SoftOx application with reference to its latest request for additional testing data.

This implies an estimated six-months delay for SoftOx’s major launch in the European markets, notwithstanding, the Swedish decision does not affect continued sales and marketing in Norway, Sweden and Denmark.

“Based on the information received in December we were confident that our data was sufficient to approve our products. We are surprised by the decision and the justification when the Agency now ask for additional tests”, says CEO Geir Almås of SoftOx Solutions AS.

The request for additional test concerns certain impurities in the formulated disinfectants. SoftOx fundamentally and scientifically disagrees with the Swedish Chemicals Agency’s assessment and request for additional tests for this data. During the evaluation process, SoftOx submitted a series of test data, generated by the accredited third-party laboratory “Sintef”, in which it was confirmed that the concerned impurities does not impact adversely the SoftOx disinfectant products. In support of this, SoftOx has also undertaken additional tests to verify its initial conclusions presented to the competent authorities during the evaluation process. These confirmatory tests (including requested tests) are anticipated to be finalized in November 2021.

Notwithstanding, SoftOx is committed to defend its scientific position and pursue its biocides submission before the national competent authorities. On advice from its scientific experts, SoftOx intends to contest and submit an administrative appeal in Sweden, and to undertake additional regulatory measures to ensure a scientifically viable and sustainable implementation of EU’s biocides regime on SoftOx products.

“SoftOx feels confident that when the requested documentation is available, the application will be duly recognized.” Says Almås.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

23 MAR 2021 15:49 CET

SoftOx Solutions AS (“SoftOx”) is pleased to announce that the enrolment of study participants for the clinical investigation «SWIS-02» has been completed. The study, which has been conducted at Bispebjerg University Hospital is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (“SWIS”) compared to Normal Saline (NS) in a human wound model. It is a confirmative study and last of two clinical studies on “SWIS”.

We are very pleased to have completed this enrolment because of the ongoing lockdown in Denmark, which were affecting our recruitment pace. “With this pivotal trial we are eagerly looking forward to examining and analyse the study data and report on the results later in Q2-2021”, says Glenn Gundersen, Medical Director of SoftOx.

SWIS is under development to become a medical device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

22 MAR 2021 08:30 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on 3rd February 2021 regarding the signing of a letter of intent, the collaboration agreement has now been finalized. SoftOx and the Norwegian Defense Research Establishment (FFI) have signed a collaboration agreement that extends until June 30th 2024. The main focus of the agreement will be on adapting the technology and products the company develops for military purposes both nationally and internationally.

SoftOx is developing a new class of antimicrobial agents, herunder range of wound care products for cleansing, prevention and treatment of wound infections, as well as a product for the treatment of respiratory tract infections. Currently the company delivers alcohol-free hand and surface disinfection products with a broader effect and more unique properties than current products on the market.

The parties have a joint vision to further develop the SoftOx applications to strengthen the military and civilian preparedness against future epidemics, chemical and biological warfare, complexed wound infections and challenging conditions in the respiratory tract.

The plan is to develop a range of military SoftOx products that will be specifically targeted for the needs of the Armed Forces and for civilian purposes in conflict areas. This work will take place in close collaboration with both our national and international civilian and military partners.

“We express high expectations for this collaboration, and we appreciate that FFI has chosen to enter into a collaboration with us. Together we will be improve the safety and the preparedness of our armed forces. We also believe that this agreement will contribute to our products becoming part of the national preparedness in the fight against infections and multi-resistant bacterias, “says CEO Geir Almås in SoftOx Solutions.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Rune Jomaas, Project Director SoftOx Solutions AS.
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About Norwegian Defense Research Establishment Norwegian Defence Research Establishment (FFI) is the prime institution responsible for defence-related research in Norway. The Establishment is the chief adviser on defence-related science and technology to the Ministry of
Defence and the Norwegian Armed Forces’ military organization. The demand for expert and flexible armed forces requires continuous renewal and Norway’s unflagging emphasize on defence technology keeps FFI busy. It is a true challenge to make significant contributions to the development of the Armed Forces – both in its principal national defence role as well as in its various roles as an effective participant in international security operations. Relevant defence research now requires international cooperation. In order to maintain a position at the forefront of science and technology within chosen sectors, FFI collaborates with national and international scientific institutions and industry. The Establishment also has a close working relationship with its partners and customers (Sourse www.ffi.no)

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance” We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

04 MAR 2021 12:28 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 3 March 2021 regarding the preliminary results of the Company’s Subsequent Offering.

The final results confirms the preliminary results reported yesterday. As a result, the Company has received valid subscriptions for in total 971,404 Offer Shares. Hence, the maximum number offered in the Subsequent Offering (181,818 offer shares) will be issued.

The allocation of the offer shares has today been completed based on the allocation criteria set out in the Company’s national prospectus dated 15 February 2021.

Notification of allocated offer shares and the corresponding amount to be paid by each subscriber will be set out in a separate letter to each subscriber, which is expected to be issued during the course of today, 4 March 2021. The payment date for the offer shares allocated is 8 March 2021 and the shares is to be paid for in accordance with the payment instructions set out in the national prospectus and subscription form.

The offer shares may not be transferred or traded until they are fully paid and the share capital increase related to the subsequent offering has been registered with Norwegian Register of Business Enterprises (Nw: Foretaksregisteret). The share capital increase is expected to be registered on or about 12 March 2021. The Offer Shares are expected to be delivered to the subscribers’ respective VPS accounts on or about the 15 March, and be tradeable on Euronext Growth Oslo on or about 16 March 2021.

Following the issuance of the offer shares issued in the Subsequent Offering and the offer shares issued in the employee offering on 24 February 2021, the Company’s share capital will be NOK 183,369.36 divided into 9,168,468 shares, each with a par value of NOK 0.02. See the attached form for notification and publication of allocation to primary insiders.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has acted as legal advisor to as the Company in connection with the Subsequent Offering.

For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS

Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site